US20110208263A1 - System and method for treating parkinson's disease and other movement disorders - Google Patents
System and method for treating parkinson's disease and other movement disorders Download PDFInfo
- Publication number
- US20110208263A1 US20110208263A1 US13/100,646 US201113100646A US2011208263A1 US 20110208263 A1 US20110208263 A1 US 20110208263A1 US 201113100646 A US201113100646 A US 201113100646A US 2011208263 A1 US2011208263 A1 US 2011208263A1
- Authority
- US
- United States
- Prior art keywords
- patient
- stimulation
- electrodes
- electrode
- gyrus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/36128—Control systems
- A61N1/36146—Control systems specified by the stimulation parameters
- A61N1/36167—Timing, e.g. stimulation onset
- A61N1/36171—Frequency
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
- A61N1/0526—Head electrodes
- A61N1/0529—Electrodes for brain stimulation
- A61N1/0531—Brain cortex electrodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
- A61N1/0526—Head electrodes
- A61N1/0529—Electrodes for brain stimulation
- A61N1/0534—Electrodes for deep brain stimulation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
- A61N1/0526—Head electrodes
- A61N1/0529—Electrodes for brain stimulation
- A61N1/0539—Anchoring of brain electrode systems, e.g. within burr hole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
- A61N1/36067—Movement disorders, e.g. tremor or Parkinson disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36014—External stimulators, e.g. with patch electrodes
- A61N1/36025—External stimulators, e.g. with patch electrodes for treating a mental or cerebral condition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/372—Arrangements in connection with the implantation of stimulators
- A61N1/375—Constructional arrangements, e.g. casings
- A61N1/3756—Casings with electrodes thereon, e.g. leadless stimulators
Definitions
- the present invention is directed toward systems and methods for treating movement disorders, such as Parkinson's Disease, that are associated with abnormal neural activity in the brain.
- a wide variety of mental and physical processes are controlled or influenced by neural activity in particular regions of the brain.
- various physical or cognitive functions are directed or affected by neural activity within the sensory or motor cortices.
- particular areas of the brain appear to have distinct functions.
- the areas of the occipital lobes relate to vision; the regions of the left interior frontal lobes relate to language; portions of the cerebral cortex appear to be consistently involved with conscious awareness, memory, and intellect; and particular regions of the cerebral cortex, the basal ganglia, the thalamus, and the motor cortex cooperatively interact to facilitate motor function control.
- Parkinson's Disease is related to the degeneration or death of dopamine producing neurons in the substantia nigra region of the basal ganglia in the brain.
- Dopamine is a neurotransmitter that transmits signals between areas of the brain. As the neurons in the substantia nigra deteriorate, the reduction in dopamine causes abnormal neural activity that results in a chronic, progressive deterioration of motor function control. Conservative estimates indicate that PD may affect more than one million individuals in the United States alone.
- PD patients typically exhibit one or more of four primary symptoms.
- One primary symptom is a tremor in an extremity (e.g., a hand) that occurs while the extremity is at rest.
- Other primary symptoms include a generalized slowness of movement (bradykinesia); increased muscle rigidity or stiffness (rigidity); and gait or balance problems (postural dysfunction).
- PD patients may exhibit secondary symptoms including: difficulty initiating or resuming movements; loss of fine motor skills; lack of arm swing on the affected side of the body while walking; foot drag on the affected side of the body; decreased facial expression; voice and/or speech changes; cognitive disorders; feelings of depression or anxiety; and/or other symptoms.
- Drug treatments or therapies may involve, for example, the administration of a dopamine precursor that is converted to dopamine within the central nervous system (i.e., Levodopa (L-dopa)). Other types of drug therapies are also available. Unfortunately, drug therapies frequently become less effective or ineffective over time for an undesirably large patient population. A PD patient may require multiple drugs in combination to extend the time period of efficacy of drug therapies.
- Drug treatments additionally have a significant likelihood of inducing undesirable physical side effects; motor function complications such as uncontrollable involuntary movements (dyskinesias) are a particularly common side effect. Furthermore, drug treatments may induce undesirable cognitive side effects such as confusion and/or hallucinations.
- Ablative surgical intervention for PD typically involves the destruction of one or more neural structures within the basal ganglia or thalamus that have become overactive because of the lack of dopamine.
- ablative surgical intervention is a very time consuming and highly invasive procedure. Potential complications associated with the procedure include risk of hemorrhage, stroke, and/or paralysis.
- PD is a progressive disease, multiple deep brain surgeries may be required as symptoms progressively worsen over time.
- ablative surgical intervention may improve a PD patient's motor function, it is not likely to completely restore normal motor function.
- ablative surgical intervention permanently destroys neural tissue, the effects of such intervention cannot be readily adjusted or “fine tuned” over time.
- Neural stimulation treatments have shown promising results for reducing some of the symptoms associated with PD.
- Neural activity is governed by electrical impulses or “action potentials” generated in and propagated by neurons. While in a quiescent state, a neuron is negatively polarized and exhibits a resting membrane potential that is typically between ⁇ 70 and ⁇ 60 mV.
- action potentials generated in and propagated by neurons. While in a quiescent state, a neuron is negatively polarized and exhibits a resting membrane potential that is typically between ⁇ 70 and ⁇ 60 mV.
- synapses Through chemical connections known as synapses, any given neuron receives excitatory and inhibitory input signals or stimuli from other neurons.
- a neuron integrates the excitatory and inhibitory input signals it receives, and generates or fires a series of action potentials in the event that the integration exceeds a threshold potential.
- a neural firing threshold for example, may be approximately ⁇ 55 mV. Action potentials propagate to the neuron's
- Neural activity in the brain can be influenced by neural stimulation, which involves the application of electrical and/or magnetic stimuli to one or more target neural populations within a patient using a waveform generator or other type of device.
- Various neural functions can thus be promoted or disrupted by applying an electrical current to one or more regions of the brain.
- researchers have attempted to treat certain neurological conditions, including PD, using electrical or magnetic stimulation signals to control or affect brain functions.
- Deep Brain Stimulation is a stimulation therapy that has been used as an alternative to drug treatments and ablative surgical therapies.
- one or more electrodes are surgically implanted into the brain proximate to deep brain or subcortical neural structures.
- the electrodes are positioned in or proximate to the ventrointermediate nucleus of the thalamus; basal ganglia structures such as the globus pallidus internalis (GPi); or the Subthalamic Nucleus (STN).
- the location of the stimulation site for the electrodes depends upon the symptoms that a patient exhibits and the severity of the symptoms.
- a pulse generator delivers a continuous or essentially continuous electrical stimulation signal having a pulse repetition frequency of approximately 100 Hz to each of two deep brain electrodes.
- the electrodes are may be positioned bilaterally on the left and right sides of the brain relative to particular neural structures such as those indicated above.
- U.S. Pat. No. 5,883,709 discloses one conventional DBS system for treating movement disorders.
- DBS therapies may significantly reduce one or more PD symptoms, particularly when combined with drug treatments, they are highly invasive procedures.
- configuring a DBS system to properly function within a patient requires two time consuming, highly invasive surgical procedures for implanting the DBS electrodes. Each such surgical procedure has essentially the same risks as those described above for ablative surgical intervention.
- DBS may not provide relief from some movement disorders.
- MCS Motor Cortex Stimulation
- MCS Motor Cortex Stimulation
- One MCS system includes a pulse generator connected to a strip electrode that is surgically implanted over a portion of only the motor cortex (precentral gyrus).
- the use of MCS to treat PD symptoms is described in Canavero, Sergio, Extradural Motor Cortex Stimulation for Advanced Parkinson's Disease: Case Report, Movement Disorders (Vol. 15, No. 1, 2000).
- MCS involves the application of stimulation signals to surface regions of the brain rather than deep neural structures
- electrode implantation procedures for MCS are significantly less invasive and time consuming than those for DBS.
- MCS may be a safer and simpler alternative to DBS for treating PD symptoms.
- Present MCS techniques fail to address or adequately consider a variety of factors that may enhance or optimize the extent to which a patient experiences short term and/or long term relief from PD symptoms.
- FIG. 1 is a flow chart illustrating methods for treating movement disorders in accordance with several embodiments of the invention.
- FIG. 2A is an image showing a mid saggital section of a brain of a patient.
- FIG. 2B is an image showing an axial view of a portion of the cerebral cortex of the brain of the patient.
- FIG. 3A is a side view of a brain of a patient with an electrode array implanted in accordance with one embodiment of the invention.
- FIG. 3B is a side view of a brain of a patient with an electrode array implanted in accordance with another embodiment of the invention.
- FIG. 3C is a lateral cross-sectional view of the cortex of a patient showing additional stimulation sites in accordance with additional embodiments of the invention.
- FIG. 4 is a side view of a brain of a patient showing one embodiment of applying neural stimulation to treat movement disorders.
- FIG. 5 is a cross-sectional view of the cerebral cortex of a patient illustrating another embodiment of treating movement disorders in accordance with the invention.
- FIG. 6 is a schematic view illustrating a system for treating movement disorders in accordance with the invention.
- FIGS. 7-9 are flow charts of methods in accordance with embodiments of the invention for treating movement disorders.
- FIGS. 1-6 Several embodiments and features of methods and systems for treating PD in accordance with the invention are set forth and described in FIGS. 1-6 . Additional embodiments and features of methods and systems for treating movement disorders, including PD, are set forth and described in FIGS. 7-9 . It will be appreciated that other embodiments in accordance with the invention can include additional procedures or different features than those shown in FIGS. 1-9 . Additionally, several embodiments of methods and systems in accordance with the invention may not include all of the features shown in these figures. Additionally, like reference numbers refer to similar or identical components or procedures throughout the figures.
- FIG. 1 is a flow chart illustrating several methods for treating movement disorders in accordance with embodiments of the invention. The methods shown in FIG. 1 are particularly useful for treating PD.
- a method 100 for treating movement disorders includes an imaging procedure 102 in which an image of the relative position between external markers and at least one of the central sulcus, precentral gyrus, and/or the postcentral gyrus of a patient is provided.
- the external markers can be anatomical features of the patient or fiducials that are attached to the patient.
- the external markers can be fiducials that are attached to the skull of the patient.
- the method 100 also includes a site selection procedure 104 that involves identifying a stimulation site relative to the external markers using the images obtained in the imaging procedure 102 .
- the stimulation site is generally proximate to the dura of the patient and over at least the precentral gyrus of the cortex. As explained in more detail below, the stimulation site can also be located over the central sulcus and/or the postcentral gyrus of the patient.
- the imaging procedure 102 and the site selection procedure 104 result in an accurate determination of the location of the underlying cortical features relative to external landmarks on the patient. As explained in more detail below, this is expected to significantly improve the efficacy of stimulation therapies for treating PD and other movement disorders.
- the method 100 can further include a stimulating procedure 110 in which neural stimulation is applied directly to the stimulation site.
- the neural stimulation can be an electrical current applied epiduraly or subduraly to the stimulation site.
- the method 100 includes an implanting procedure 108 in which an electrode is implanted at least proximate to the dura at the stimulation site.
- the implanting procedure 108 accordingly occurs after the site selection procedure 104 and before the stimulating procedure 110 .
- the neural stimulation of the stimulating procedure 110 can be transcutaneous magnetic stimulation.
- FIGS. 2A and 2B are examples of images provided by the imaging procedure 102 ( FIG. 1 ) for use in the site selection procedure 104 ( FIG. 1 ).
- the imaging procedure 102 can be Magnetic Resonance Imaging (MRI), CT imaging, fMRI imaging or other suitable processes.
- FIG. 2A is a magnetic resonance image 200 a showing the brain 210 of a patient P along a mid saggital section.
- the image 200 a shows the location of various features of the cerebral cortex 220 relative to fiducial markers 230 attached to the skull of the patient P.
- One embodiment of the site selection procedure 104 involves locating the pars marginalis sulcus 240 of the cortex 220 using the image 200 a of the mid saggital section.
- This particular image is useful because the pars marginalis sulcus is the only sulcus that can be followed into the interhemispheric fissure in this view. Based on the location of the pars marginalis sulcus shown in image 200 a , this position can be extrapolated to an axial image to determine the location of the central sulcus, the postcentral gyrus, and the precentral gyrus on the cortex 220 relative to the external markers.
- FIG. 2B is a magnetic resonance image 200 b of a brain taken along an axial section.
- the pars marginalis sulcus 240 appears as a small, symmetrical sulcus extending bilaterally out from the interhemispheric fissure.
- the position of the postcentral sulcus 242 can be determined by moving laterally (i.e., outward) from the pars marginalis sulcus 240 .
- the postcentral sulcus 242 forms the posterior boundary of the postcentral gyrus 260 , and thus the central sulcus 244 can be identified as the anterior boundary of the postcentral gyrus 260 .
- the central sulcus 244 forms the posterior boundary of the precentral gyrus 250 and the precentral sulcus 246 forms the anterior boundary of the precentral gyrus 250 .
- the site selection procedure 104 can also involve identifying an external region on the patient relative to the location of the central sulcus 244 . After identifying the location of the central sulcus 244 on the image 200 b , the location of the central sulcus 244 is noted relative to the external markers 230 . Using standard neuronavigational MRI techniques, the data from the images can be transferred into an intraoperative navigational station that locates the external position on the scalp of the patient overlying the central sulcus 244 relative to the position of the fiducial markers 230 . The external position accordingly defines the general area where stimulation will be applied. The actual stimulation site is generally under the scalp at an area that is proximate to the dura of the patient and aligned with the external position identified on the patient.
- FIGS. 3A-3C illustrate several embodiments of the implanting procedure 108 for implanting electrodes at a stimulation site.
- FIG. 3A is a schematic side view of the brain 200 illustrating one embodiment of implanting a linear electrode array 310 at a stimulation site 300 a proximate to the dura and over the precentral gyrus 250 .
- the linear electrode array 310 has a plurality of electrodes 320 arranged along a single row, but in other embodiments the linear electrode array 310 may have only one electrode 320 .
- the electrode array 310 can have only a single electrode 320 (i.e., a contact) instead of an array of electrodes.
- the electrodes 320 can be circular contacts each having a surface area of approximately 5 mm.sup.2 and being spaced apart by about 7.5 mm. In other embodiments, the electrodes can be other shapes and have other configurations, such as an elongated electrode.
- the linear electrode array 310 has a lead 322 coupled to the electrodes 320 and an implanted pulse generator implanted above the neck or at a subclavicular location. The lead 322 is tunneled through the patient using standard techniques.
- the linear electrode array 310 can be positioned so that the row of electrodes 320 extends in a medial to lateral direction generally parallel with the central sulcus 244 .
- the electrodes 320 are also superimposed over the precentral gyrus 250 .
- the linear electrode array 310 generally has a plurality of electrodes 320 to provide extensive coverage over the precentral gyrus 250 and thus activate a large number of neurons in the motor cortex (e.g., use all of the electrodes) or only discrete populations of neurons in the motor cortex with only a single implantation of an electrode array (e.g., activate only selected electrodes).
- the electrode array 310 can be implanted so that the electrodes are proximate to the dura such as at an epidural or subdural location.
- FIG. 3B is a side-view of the brain 200 illustrating another embodiment for implanting an electrode array proximate to the dura at the stimulation site.
- the stimulation site 300 b is located over the precentral gyrus 250 and the postcentral gyrus 260 .
- a grid electrode array 330 is implanted at the stimulation site 300 b proximate to the dura.
- the grid electrode array 330 can include a plurality of first electrodes 340 a arranged along a first row and a plurality of second electrodes 340 b arranged along a second row.
- the first and second rows of electrodes 340 a - b can extend generally at an oblique angle relative to the central sulcus 244 .
- the grid electrode array 330 also has a lead 342 coupled to the electrodes 340 a - b and an implanted pulse generator. As with the linear electrode array 310 , the grid electrode array 330 can be implanted so that the electrodes are proximate to the dura.
- the stimulation sites 300 a and 300 b shown on FIGS. 3A and 3B are located relative to the precentral gyrus, the central sulcus 244 , and/or the postcentral gyrus 260 using the imaging and site selection procedures 102 - 104 described above with respect to FIGS. 2A and 2B .
- This enables the stimulation to be applied to desired locations on the cortex with much greater accuracy than previous methods that rely solely on the external anatomical features of the patient.
- the greater precision of locating the stimulation sites 300 a - b for implanting the electrode arrays is expected to significantly enhance the efficacy of stimulation treatments for treating PD and other movement disorders.
- the efficacy of the stimulation treatment can also be enhanced by locating the stimulation sites 300 a - b at a desired superior-inferior location along the precentral gyrus and/or the postcentral gyrus relative to the sylvian fissure and the interhemispherical fissure.
- FIG. 3C is a lateral section view taken along line 3 C- 3 C of FIG. 3B .
- the stimulation site can be located more towards the sylvian fissure 370 for treating predominant symptoms of speech disorders or towards the interhemispherical fissure 380 for treating predominant symptoms of gait disorders.
- the superior-inferior location along the precentral gyrus 250 and/or the postcentral gyrus 260 can accordingly be predicated by the symptomotology of the function that is affected by the movement disorder.
- FIG. 4 is a side view illustrating several embodiments of applying neural stimulation directly to the stimulation site. More specifically, FIG. 4 illustrates the grid electrode array 330 positioned at the stimulation site 300 b over the precentral gyrus 250 , the central sulcus 244 , and the postcentral gyrus 260 .
- the neural stimulation can comprise passing an electrical current through the electrodes 340 a - b to the stimulation site 300 b .
- the electrical current can be applied to a single one of the electrodes 340 a or 340 b to provide a monopolar pulse of current to a small area of the cortex 220 .
- a return electrode can be positioned elsewhere in the patient, such as on the other side of the patient's brain or at a subclavicular location.
- the return electrode can be a portion of a pulse generator or another electrode implanted elsewhere in the patient.
- electrical current can be passed through all of the electrodes 340 a - b or only a subset of these electrodes to activate larger or different populations of neurons.
- the potential applied to the electrodes 340 a - b can be the same across all of the activated electrodes to provide monopolar stimulation at the stimulation site.
- This embodiment also typically has a return electrode implanted elsewhere in the patient as explained above.
- some of the electrodes can be biased with a positive polarity and other electrodes can be biased with a negative polarity.
- the first electrodes 340 a can be biased with one polarity and the second electrodes 340 b can be biased with an opposite polarity.
- This embodiment provides a bipolar stimulation to the cortex 220 .
- the particular configuration of the electrodes can be optimized after implantation to provide the most efficacious therapy for the patient.
- the stimulus can have a waveform with a current of approximately 0.5 mA to 10 mA, a pulse duration of approximately 20 microseconds-500 milliseconds, and a frequency of approximately 10 Hz-200 Hz.
- the electrical stimulus can have a current of approximately 3 mA to 8 mA, a pulse duration of 100 microseconds-200 microseconds, and a frequency of approximately 20 Hz-50 Hz.
- the current can be approximately 4 mA to 6 mA, and more particularly approximately around 5 mA.
- the waveforms of any of the foregoing embodiments can have a voltage of approximately: 0.25 V to 5.0 V in many applications; 0.5 V to 3.5 V in more specific applications; 2.0 V to 3.5 V in still more specific applications; and 3.0 V in a particular application.
- the pulse duration can be in the range of 90-180 microseconds.
- the stimulus can be applied for a period of 0.5 hour-4.0 hours, and in many applications the therapy is applied for a period of approximately 0.5 hour-1.5 hours. In other embodiments, the stimulation can be applied continuously, or only during waking periods but not sleeping periods. Examples of specific stimulation protocols for use with an electrode array at an epidural stimulation site over the precentral gyrus are as follows:
- An electrical stimulus having a current of approximately 0.1 mA to 10 mA, an impedance of 600 to 1000 Ohms, a pulse duration of 160 microseconds, and a frequency of approximately 130 Hz.
- the therapy is not applied continuously, but rather during 30-60 minute intervals.
- the stimulus has a current of approximately 0.1 mA to 10 mA, a pulse duration of approximately 150-180 microseconds, and a frequency of approximately 25 Hz-31 Hz.
- the stimulus is applied continuously during waking periods, but it is discontinued during sleeping periods to conserve battery life of the implanted pulse generator.
- the stimulus has a current of approximately 2 mA to 4 mA, a pulse duration of approximately 90 microseconds, and a frequency of approximately 30 Hz. This stimulus is applied continuously during waking and sleeping periods, but it can be discontinued during sleeping periods.
- FIG. 5 illustrates another aspect of an embodiment of the invention.
- the symptoms are manifested to a greater extent on one side of the body than the other.
- a patient may have a tremor in both hands, but usually one hand will have a tremor worse than the other hand.
- the patient's body is divided into a first side and a second side opposite the first side relative to a medial axis (e.g., right side-left side), and only one side of the cortex is stimulated to treat the disorder on both sides of the body.
- This embodiment can be carried out by implanting the electrode array 320 or 330 at a stimulation site on only the first side of the patient when the disorder of a motor function is greater on the second side of the patient.
- this embodiment can also include implanting one or more electrodes at a homologous location on the contralateral hemisphere relative to the movement disorder.
- the single electrode array can provide a bilateral affect that not only treats the disorder associated with the second side of the patient, but also treats the disorder associated with the first side of the patient. For example, if the patient experiences a bilateral tremor that is worse on the right side compared to the left side, then an electrode array can be implanted proximate to the dura over only the left hemisphere of the cortex 220 .
- the bilateral effect of the single-side stimulation may be enhanced using monopolar stimulation techniques in which the electrodes are biased with the same polarity.
- the bilateral effect may be caused by activation of commissural neurons (large pyramidal cells) in the deep portion of layer III of the motor cortex. Subsequent to activation, these neurons can depolarize complimentary cell groups in the contralateral hemisphere via the corpus callosum.
- the electrode may maximally effect the contralateral lower extremity musculature and also the ipsilateral muscle groups. It is expected that the placement should be sufficiently remote from the interhemispheric fissure to avoid venous damage or occlusion.
- the single-side stimulation site may be particularly advantageous in certain situations because it requires only a single electrode array to be planted relative to a single hemisphere of the cortex 220 of the patient. This reduces the invasiveness and the risk associated with surgery.
- FIG. 5 also illustrates another embodiment in which an electrode array 330 a (shown in broken line) is implanted at a site on the ipsilateral hemisphere of the brain relative to the side of the body most affected by the movement disorder.
- the electrode array 330 a can be implanted by itself such that it is the only electrode array. In a different embodiment, however, both of the electrode arrays 330 and 330 a can be implanted at homologous and/or non-homologous regions relative to the movement disorders on both hemispheres of the brain. Additionally, the electrode array 330 a can have only a single electrode as described above with respect to the electrode array 330 .
- FIG. 6 is a schematic view illustrating embodiments of systems for treating movement disorders in accordance with the invention.
- the system can include the linear electrode array 310 coupled to an implanted pulse generator 600 a implanted at a subclavicular location in the patient P.
- the grid electrode array 330 can be substituted for the linear electrode array 310 .
- a lead 322 / 342 is tunneled between the implanted pulse generator 600 a and the electrode array.
- the system has an implanted above-neck pulse generator 600 b that is smaller and configured to be implanted at a location above the neck of the patient P.
- the above-neck implanted pulse generator 600 b can be planted posteriorly of the ear of the patient P.
- the electrode arrays 310 or 330 are implanted underneath the scull S of the patient P at an epidural or subdural stimulation site as set forth above.
- FIG. 7 is a flow chart illustrating additional methods for treating movement disorders in accordance with additional embodiments of the invention.
- a method 700 includes a site selection procedure 710 including determining a cortical site related to a movement disorder of an afflicted body part of the patient.
- the site selection procedure 710 includes obtaining a representation of neural activity occurring in the cortex of the patient, and correlating an area of neural activity with the afflicted body part.
- the site selection procedure 710 can include providing a representation of neural activity in the cortex of the brain of a patient, identifying a neural activation area on the representation considered to be related to a body part of the patient affected by a movement disorder, and selecting the cortical site on the patient by referencing the identified neural activation area to the anatomy of the patient.
- a representation of neural activity occurring in the cortex can be obtained or provided by imaging neural activity in the cortex using a neural imaging technique while performing a task related to the affected body part.
- the representation of neural activity in the cortex can be obtained by imaging cortical neural activity while (a) the patient mentally concentrates on moving the affected body part, (b) the affected body part is moved by the patient, (c) an electrical pulse is applied to the affected body part, and/or (d) another person or device passively moves the affected body part.
- obtaining a representation of neural activity in the brain can include collecting data of neural activity in the cortex of the patient related to the affected body part without necessarily generating an image. The collected data can be stored in a memory and processed to generate anatomical coordinates and/or an image of the neural activity.
- the site selection procedure 710 is expected to increase the efficacy of the stimulation therapy and provide additional benefits. For example, having the patient concentrate on moving the affected body part or actually move the affected body part while imaging the neural activity in the cortex is expected to provide an accurate indication of the area(s) in the cortex where neural activity for controlling the motor function of the affected body part is performed. Similarly, applying an electrical pulse to the affected body part while imaging neural activity in the cortex is expected to provide another accurate indication of where neural activity occurs for controlling the motor function of the affected body part. By providing an accurate indication of the location of neural activity related to the affected body part, the method 700 is expected to operate at low electrical potentials to reduce unwanted collateral stimulation of neurons and prolong the battery life of an implanted pulse generator. Moreover, such precise location of the electrodes enhances the efficacy of the stimulation procedure because the neurons that are involved in controlling the affected body part are more likely to be stimulated in a controlled manner.
- the method 700 further includes a stimulation procedure 720 that involves applying neural stimulation directly to the cortical site.
- the stimulation procedure can be preceded by implanting an electrode unit proximate to the dura mater at the cortical site.
- the electrode unit can have a single electrode or an array with a plurality of electrodes as explained above.
- the stimulation procedure 720 can include any of the electrical waveforms set forth above.
- the stimulation procedure can include applying an electrical waveform having a frequency of approximately 5-1000 Hz.
- the stimulation procedure 720 can include applying an electrical waveform having a frequency of approximately 10-60 Hz, and more specifically at a frequency of 20 Hz or 50 Hz. Other examples could be at higher frequencies of 90-150 Hz or in a narrower range of 100-120 Hz.
- FIG. 8 is a flow chart illustrating another method for treating movement disorders in accordance with additional embodiments of the invention.
- the method 800 includes performing a craniotomy 810 to expose a cortical location related to an affected body part.
- the craniotomy 810 can expose subdural or epidural tissue.
- the method 800 further includes a test procedure 820 and a mapping procedure 830 .
- the test procedure 820 includes applying a test stimulation waveform to a plurality of discrete regions of the cortical location.
- a single electrode is moved to different discrete locations of the cortical region exposed by the craniotomy and an electrical pulse is applied to each location separately.
- the test procedure 820 includes implanting an electrode array having a plurality of electrodes such that each electrode is adjacent to a discrete region of the cortical location.
- This embodiment includes applying the test stimulation waveform separately to one or more of the individual electrodes in different combinations. Both of these embodiments of the test procedure 820 apply the test stimulation waveform to the discrete regions of the cortical location at separate time periods.
- the mapping procedure 830 includes (a) verifying the proper electrode location and/or (b) measuring the efficacy of the test stimulation waveforms as they are applied to the different discrete regions of the cortical location.
- the mapping procedure can occur while the patient is under an anesthetic, and it can also apply electrical pulses at a current that is sufficient to provoke a response.
- the mapping procedure 830 can further include monitoring the decrease and/or increase in the tremor of a body part affected by PD as the test waveform is applied to the different discrete regions.
- the method 800 further includes a selection procedure 840 in which one or more of the discrete regions is selected based upon the efficacy of the discrete regions for treating the movement disorder.
- the selection procedure 840 accordingly determines which electrode(s) receive electrical pulses for treating the movement disorder.
- the method 800 accordingly, further includes a stimulation procedure 850 including applying a therapy stimulation waveform to the selected regions of the cortical location.
- FIG. 9 is a flow chart of another method 900 for treating movement disorders in accordance with another embodiment of the invention.
- the method 900 includes an implanting procedure 910 in which an electrode is implanted at a cortical stimulation site based upon a standard correlation between cortical neural activity and motor functions in humans.
- an electrode array can be implanted at a cortical stimulation site based upon the standard correlation between cortical neural activity and motor functions in humans, and in particular the standard location for neural activity in humans for motor control of the affected body part.
- the implanting procedure 910 accordingly does not necessarily need to select the stimulation site based upon an image, data or other information to obtain or provide a representation of neural activity in the brain related to the affected body part.
- the method 900 further includes a stimulation procedure 920 involving applying electrical stimulation to the cortical location to treat a movement disorder.
- the leads of the electrode arrays may be coupled to an external pulse generator instead of an implanted pulse generator.
- the stimulation site can be selected at an area of the cortex that is not normally associated with the function of the body part(s) affected by the movement disorder (e.g., non-homologous regions). This embodiment accordingly places the electrodes at other neurofunctional areas that control other movement and/or speech functions.
- electrode arrays having different configurations of electrodes can be implanted on opposing hemispheres of the cortex.
- transcutaneous magnetic stimulation can be applied to the selected stimulation site before implanting the electrodes to estimate the response and refine the location of the stimulation site.
- a stimulation site can be selected using an imaging modality (e.g., MRI, fMFI, etc.) and/or externally estimating the site according to the normal location for neural activity associated with the movement disorder, and then transcutaneous magnetic stimulation can be applied at the stimulation site and/or neighboring areas before implanting the electrode.
- the precise location for the stimulation site can then be modified according to the results of the transcutaneous magnetic stimulation in a manner similar to the mapping procedure 830 described above. Accordingly, the invention is not limited except as by the appended claims.
Abstract
Systems and methods for treating movement disorders using cortical stimulation. In one embodiment, a method for treating movement disorders comprises determining a site at the cortex of the brain of a patient related to a movement disorder of an afflicted body part. The site can be determined by obtaining a representation of neural activity occurring in the cortex of the patient and correlating an area of neural activity with the afflicted body part. The method can also include applying neural stimulation, such as electrical or magnetic waveforms, directly to the site.
Description
- This application is a continuation of U.S. application Ser. No. 11/867,654, filed Oct. 4, 2007, which is a continuation of U.S. application Ser. No. 10/731,731, filed Dec. 9, 2003, now U.S. Pat. No. 7,299,096, which is a continuation-in-part of U.S. application Ser. No. 09/802,808, filed Mar. 8, 2001, now U.S. Pat. No. 7,010,351, and claims the benefit of U.S. Provisional Application No. 60/432,073, filed Dec. 9, 2002, all of which are incorporated herein by reference.
- The present invention is directed toward systems and methods for treating movement disorders, such as Parkinson's Disease, that are associated with abnormal neural activity in the brain.
- A wide variety of mental and physical processes are controlled or influenced by neural activity in particular regions of the brain. For example, various physical or cognitive functions are directed or affected by neural activity within the sensory or motor cortices. Across most individuals, particular areas of the brain appear to have distinct functions. In the majority of people, for example, the areas of the occipital lobes relate to vision; the regions of the left interior frontal lobes relate to language; portions of the cerebral cortex appear to be consistently involved with conscious awareness, memory, and intellect; and particular regions of the cerebral cortex, the basal ganglia, the thalamus, and the motor cortex cooperatively interact to facilitate motor function control.
- Many problems or abnormalities with body functions can be caused by damage, disease, and/or disorders in the brain. For example, Parkinson's Disease (PD) is related to the degeneration or death of dopamine producing neurons in the substantia nigra region of the basal ganglia in the brain. Dopamine is a neurotransmitter that transmits signals between areas of the brain. As the neurons in the substantia nigra deteriorate, the reduction in dopamine causes abnormal neural activity that results in a chronic, progressive deterioration of motor function control. Conservative estimates indicate that PD may affect more than one million individuals in the United States alone.
- PD patients typically exhibit one or more of four primary symptoms. One primary symptom is a tremor in an extremity (e.g., a hand) that occurs while the extremity is at rest. Other primary symptoms include a generalized slowness of movement (bradykinesia); increased muscle rigidity or stiffness (rigidity); and gait or balance problems (postural dysfunction). In addition to or in lieu of these primary symptoms, PD patients may exhibit secondary symptoms including: difficulty initiating or resuming movements; loss of fine motor skills; lack of arm swing on the affected side of the body while walking; foot drag on the affected side of the body; decreased facial expression; voice and/or speech changes; cognitive disorders; feelings of depression or anxiety; and/or other symptoms.
- Effectively treating PD or other movement disorders related to neurological conditions can be very difficult. Current treatments for PD symptoms include drugs, ablative surgical intervention, and/or neural stimulation. Drug treatments or therapies may involve, for example, the administration of a dopamine precursor that is converted to dopamine within the central nervous system (i.e., Levodopa (L-dopa)). Other types of drug therapies are also available. Unfortunately, drug therapies frequently become less effective or ineffective over time for an undesirably large patient population. A PD patient may require multiple drugs in combination to extend the time period of efficacy of drug therapies. Drug treatments additionally have a significant likelihood of inducing undesirable physical side effects; motor function complications such as uncontrollable involuntary movements (dyskinesias) are a particularly common side effect. Furthermore, drug treatments may induce undesirable cognitive side effects such as confusion and/or hallucinations.
- Ablative surgical intervention for PD typically involves the destruction of one or more neural structures within the basal ganglia or thalamus that have become overactive because of the lack of dopamine. Unfortunately, such neural structures reside deep within the brain, and hence ablative surgical intervention is a very time consuming and highly invasive procedure. Potential complications associated with the procedure include risk of hemorrhage, stroke, and/or paralysis. Moreover, because PD is a progressive disease, multiple deep brain surgeries may be required as symptoms progressively worsen over time. Although ablative surgical intervention may improve a PD patient's motor function, it is not likely to completely restore normal motor function. Furthermore, since ablative surgical intervention permanently destroys neural tissue, the effects of such intervention cannot be readily adjusted or “fine tuned” over time.
- Neural stimulation treatments have shown promising results for reducing some of the symptoms associated with PD. Neural activity is governed by electrical impulses or “action potentials” generated in and propagated by neurons. While in a quiescent state, a neuron is negatively polarized and exhibits a resting membrane potential that is typically between −70 and −60 mV. Through chemical connections known as synapses, any given neuron receives excitatory and inhibitory input signals or stimuli from other neurons. A neuron integrates the excitatory and inhibitory input signals it receives, and generates or fires a series of action potentials in the event that the integration exceeds a threshold potential. A neural firing threshold, for example, may be approximately −55 mV. Action potentials propagate to the neuron's synapses and are then conveyed to other synaptically connected neurons.
- Neural activity in the brain can be influenced by neural stimulation, which involves the application of electrical and/or magnetic stimuli to one or more target neural populations within a patient using a waveform generator or other type of device. Various neural functions can thus be promoted or disrupted by applying an electrical current to one or more regions of the brain. As a result, researchers have attempted to treat certain neurological conditions, including PD, using electrical or magnetic stimulation signals to control or affect brain functions.
- Deep Brain Stimulation (DBS) is a stimulation therapy that has been used as an alternative to drug treatments and ablative surgical therapies. In DBS, one or more electrodes are surgically implanted into the brain proximate to deep brain or subcortical neural structures. For treating PD or other movement disorders, the electrodes are positioned in or proximate to the ventrointermediate nucleus of the thalamus; basal ganglia structures such as the globus pallidus internalis (GPi); or the Subthalamic Nucleus (STN). The location of the stimulation site for the electrodes depends upon the symptoms that a patient exhibits and the severity of the symptoms.
- In a typical DBS system, a pulse generator delivers a continuous or essentially continuous electrical stimulation signal having a pulse repetition frequency of approximately 100 Hz to each of two deep brain electrodes. The electrodes are may be positioned bilaterally on the left and right sides of the brain relative to particular neural structures such as those indicated above. U.S. Pat. No. 5,883,709 discloses one conventional DBS system for treating movement disorders.
- Although DBS therapies may significantly reduce one or more PD symptoms, particularly when combined with drug treatments, they are highly invasive procedures. In general, configuring a DBS system to properly function within a patient requires two time consuming, highly invasive surgical procedures for implanting the DBS electrodes. Each such surgical procedure has essentially the same risks as those described above for ablative surgical intervention. Moreover, DBS may not provide relief from some movement disorders.
- Motor Cortex Stimulation (MCS) is another type of brain stimulation treatment that has been proposed for treating Parkinson's Disease. MCS involves the application of stimulation signals to the motor cortex of a patient. One MCS system includes a pulse generator connected to a strip electrode that is surgically implanted over a portion of only the motor cortex (precentral gyrus). The use of MCS to treat PD symptoms is described in Canavero, Sergio, Extradural Motor Cortex Stimulation for Advanced Parkinson's Disease: Case Report, Movement Disorders (Vol. 15, No. 1, 2000).
- Because MCS involves the application of stimulation signals to surface regions of the brain rather than deep neural structures, electrode implantation procedures for MCS are significantly less invasive and time consuming than those for DBS. As a result, MCS may be a safer and simpler alternative to DBS for treating PD symptoms. Present MCS techniques, however, fail to address or adequately consider a variety of factors that may enhance or optimize the extent to which a patient experiences short term and/or long term relief from PD symptoms.
-
FIG. 1 is a flow chart illustrating methods for treating movement disorders in accordance with several embodiments of the invention. -
FIG. 2A is an image showing a mid saggital section of a brain of a patient. -
FIG. 2B is an image showing an axial view of a portion of the cerebral cortex of the brain of the patient. -
FIG. 3A is a side view of a brain of a patient with an electrode array implanted in accordance with one embodiment of the invention. -
FIG. 3B is a side view of a brain of a patient with an electrode array implanted in accordance with another embodiment of the invention. -
FIG. 3C is a lateral cross-sectional view of the cortex of a patient showing additional stimulation sites in accordance with additional embodiments of the invention. -
FIG. 4 is a side view of a brain of a patient showing one embodiment of applying neural stimulation to treat movement disorders. -
FIG. 5 is a cross-sectional view of the cerebral cortex of a patient illustrating another embodiment of treating movement disorders in accordance with the invention. -
FIG. 6 is a schematic view illustrating a system for treating movement disorders in accordance with the invention. -
FIGS. 7-9 are flow charts of methods in accordance with embodiments of the invention for treating movement disorders. - The following disclosure describes several embodiments and systems for treating PD and other movement disorders using cortical stimulation. Several embodiments and features of methods and systems for treating PD in accordance with the invention are set forth and described in
FIGS. 1-6 . Additional embodiments and features of methods and systems for treating movement disorders, including PD, are set forth and described inFIGS. 7-9 . It will be appreciated that other embodiments in accordance with the invention can include additional procedures or different features than those shown inFIGS. 1-9 . Additionally, several embodiments of methods and systems in accordance with the invention may not include all of the features shown in these figures. Additionally, like reference numbers refer to similar or identical components or procedures throughout the figures. -
FIG. 1 is a flow chart illustrating several methods for treating movement disorders in accordance with embodiments of the invention. The methods shown inFIG. 1 are particularly useful for treating PD. In one embodiment, amethod 100 for treating movement disorders includes animaging procedure 102 in which an image of the relative position between external markers and at least one of the central sulcus, precentral gyrus, and/or the postcentral gyrus of a patient is provided. The external markers can be anatomical features of the patient or fiducials that are attached to the patient. For example, the external markers can be fiducials that are attached to the skull of the patient. Themethod 100 also includes asite selection procedure 104 that involves identifying a stimulation site relative to the external markers using the images obtained in theimaging procedure 102. The stimulation site is generally proximate to the dura of the patient and over at least the precentral gyrus of the cortex. As explained in more detail below, the stimulation site can also be located over the central sulcus and/or the postcentral gyrus of the patient. Theimaging procedure 102 and thesite selection procedure 104 result in an accurate determination of the location of the underlying cortical features relative to external landmarks on the patient. As explained in more detail below, this is expected to significantly improve the efficacy of stimulation therapies for treating PD and other movement disorders. - The
method 100 can further include a stimulatingprocedure 110 in which neural stimulation is applied directly to the stimulation site. The neural stimulation can be an electrical current applied epiduraly or subduraly to the stimulation site. When the neural stimulation is an electrical current applied directly to the cerebral cortex proximate to the dura, themethod 100 includes an implantingprocedure 108 in which an electrode is implanted at least proximate to the dura at the stimulation site. The implantingprocedure 108 accordingly occurs after thesite selection procedure 104 and before the stimulatingprocedure 110. In other embodiments, the neural stimulation of the stimulatingprocedure 110 can be transcutaneous magnetic stimulation. Several aspects of each of the procedures 102-110 are described in more detail below with respect toFIGS. 2A-5 . -
FIGS. 2A and 2B are examples of images provided by the imaging procedure 102 (FIG. 1 ) for use in the site selection procedure 104 (FIG. 1 ). Theimaging procedure 102 can be Magnetic Resonance Imaging (MRI), CT imaging, fMRI imaging or other suitable processes.FIG. 2A is amagnetic resonance image 200 a showing thebrain 210 of a patient P along a mid saggital section. Theimage 200 a shows the location of various features of thecerebral cortex 220 relative tofiducial markers 230 attached to the skull of the patient P. One embodiment of thesite selection procedure 104 involves locating the pars marginalissulcus 240 of thecortex 220 using theimage 200 a of the mid saggital section. This particular image is useful because the pars marginalis sulcus is the only sulcus that can be followed into the interhemispheric fissure in this view. Based on the location of the pars marginalis sulcus shown inimage 200 a, this position can be extrapolated to an axial image to determine the location of the central sulcus, the postcentral gyrus, and the precentral gyrus on thecortex 220 relative to the external markers. - The site selection procedure 104 (
FIG. 1 ) continues with an axial image of thecortex 220.FIG. 2B is amagnetic resonance image 200 b of a brain taken along an axial section. Referring toFIG. 2B , the pars marginalissulcus 240 appears as a small, symmetrical sulcus extending bilaterally out from the interhemispheric fissure. Based upon the position of the pars marginalissulcus 240, the position of thepostcentral sulcus 242 can be determined by moving laterally (i.e., outward) from the pars marginalissulcus 240. Thepostcentral sulcus 242 forms the posterior boundary of thepostcentral gyrus 260, and thus thecentral sulcus 244 can be identified as the anterior boundary of thepostcentral gyrus 260. Similarly, thecentral sulcus 244 forms the posterior boundary of theprecentral gyrus 250 and theprecentral sulcus 246 forms the anterior boundary of theprecentral gyrus 250. - The
site selection procedure 104 can also involve identifying an external region on the patient relative to the location of thecentral sulcus 244. After identifying the location of thecentral sulcus 244 on theimage 200 b, the location of thecentral sulcus 244 is noted relative to theexternal markers 230. Using standard neuronavigational MRI techniques, the data from the images can be transferred into an intraoperative navigational station that locates the external position on the scalp of the patient overlying thecentral sulcus 244 relative to the position of thefiducial markers 230. The external position accordingly defines the general area where stimulation will be applied. The actual stimulation site is generally under the scalp at an area that is proximate to the dura of the patient and aligned with the external position identified on the patient. -
FIGS. 3A-3C illustrate several embodiments of the implantingprocedure 108 for implanting electrodes at a stimulation site.FIG. 3A , more specifically, is a schematic side view of thebrain 200 illustrating one embodiment of implanting alinear electrode array 310 at astimulation site 300 a proximate to the dura and over theprecentral gyrus 250. In this embodiment, thelinear electrode array 310 has a plurality ofelectrodes 320 arranged along a single row, but in other embodiments thelinear electrode array 310 may have only oneelectrode 320. For example, theelectrode array 310 can have only a single electrode 320 (i.e., a contact) instead of an array of electrodes. Theelectrodes 320 can be circular contacts each having a surface area of approximately 5 mm.sup.2 and being spaced apart by about 7.5 mm. In other embodiments, the electrodes can be other shapes and have other configurations, such as an elongated electrode. Thelinear electrode array 310 has a lead 322 coupled to theelectrodes 320 and an implanted pulse generator implanted above the neck or at a subclavicular location. Thelead 322 is tunneled through the patient using standard techniques. - The
linear electrode array 310 can be positioned so that the row ofelectrodes 320 extends in a medial to lateral direction generally parallel with thecentral sulcus 244. Theelectrodes 320 are also superimposed over theprecentral gyrus 250. Thelinear electrode array 310 generally has a plurality ofelectrodes 320 to provide extensive coverage over theprecentral gyrus 250 and thus activate a large number of neurons in the motor cortex (e.g., use all of the electrodes) or only discrete populations of neurons in the motor cortex with only a single implantation of an electrode array (e.g., activate only selected electrodes). Theelectrode array 310 can be implanted so that the electrodes are proximate to the dura such as at an epidural or subdural location. -
FIG. 3B is a side-view of thebrain 200 illustrating another embodiment for implanting an electrode array proximate to the dura at the stimulation site. In this embodiment, thestimulation site 300 b is located over theprecentral gyrus 250 and thepostcentral gyrus 260. Agrid electrode array 330 is implanted at thestimulation site 300 b proximate to the dura. Thegrid electrode array 330 can include a plurality offirst electrodes 340 a arranged along a first row and a plurality ofsecond electrodes 340 b arranged along a second row. The first and second rows of electrodes 340 a-b can extend generally at an oblique angle relative to thecentral sulcus 244. Thegrid electrode array 330 also has a lead 342 coupled to the electrodes 340 a-b and an implanted pulse generator. As with thelinear electrode array 310, thegrid electrode array 330 can be implanted so that the electrodes are proximate to the dura. - One aspect of several embodiments of the invention is that the
stimulation sites FIGS. 3A and 3B are located relative to the precentral gyrus, thecentral sulcus 244, and/or thepostcentral gyrus 260 using the imaging and site selection procedures 102-104 described above with respect toFIGS. 2A and 2B . This enables the stimulation to be applied to desired locations on the cortex with much greater accuracy than previous methods that rely solely on the external anatomical features of the patient. The greater precision of locating the stimulation sites 300 a-b for implanting the electrode arrays is expected to significantly enhance the efficacy of stimulation treatments for treating PD and other movement disorders. - Another aspect of several embodiments is that the efficacy of the stimulation treatment can also be enhanced by locating the stimulation sites 300 a-b at a desired superior-inferior location along the precentral gyrus and/or the postcentral gyrus relative to the sylvian fissure and the interhemispherical fissure.
FIG. 3C , for example, is a lateral section view taken alongline 3C-3C ofFIG. 3B . The stimulation site can be located more towards thesylvian fissure 370 for treating predominant symptoms of speech disorders or towards theinterhemispherical fissure 380 for treating predominant symptoms of gait disorders. The superior-inferior location along theprecentral gyrus 250 and/or thepostcentral gyrus 260 can accordingly be predicated by the symptomotology of the function that is affected by the movement disorder. -
FIG. 4 is a side view illustrating several embodiments of applying neural stimulation directly to the stimulation site. More specifically,FIG. 4 illustrates thegrid electrode array 330 positioned at thestimulation site 300 b over theprecentral gyrus 250, thecentral sulcus 244, and thepostcentral gyrus 260. The neural stimulation can comprise passing an electrical current through the electrodes 340 a-b to thestimulation site 300 b. In one embodiment, the electrical current can be applied to a single one of theelectrodes cortex 220. A return electrode can be positioned elsewhere in the patient, such as on the other side of the patient's brain or at a subclavicular location. The return electrode can be a portion of a pulse generator or another electrode implanted elsewhere in the patient. In other embodiments, electrical current can be passed through all of the electrodes 340 a-b or only a subset of these electrodes to activate larger or different populations of neurons. In these embodiments, the potential applied to the electrodes 340 a-b can be the same across all of the activated electrodes to provide monopolar stimulation at the stimulation site. This embodiment also typically has a return electrode implanted elsewhere in the patient as explained above. In other embodiments, some of the electrodes can be biased with a positive polarity and other electrodes can be biased with a negative polarity. For example, thefirst electrodes 340 a can be biased with one polarity and thesecond electrodes 340 b can be biased with an opposite polarity. This embodiment provides a bipolar stimulation to thecortex 220. The particular configuration of the electrodes can be optimized after implantation to provide the most efficacious therapy for the patient. - The particular waveform of the stimuli depends upon the symptoms of the particular patients. In one embodiment, the stimulus can have a waveform with a current of approximately 0.5 mA to 10 mA, a pulse duration of approximately 20 microseconds-500 milliseconds, and a frequency of approximately 10 Hz-200 Hz. In other embodiments, the electrical stimulus can have a current of approximately 3 mA to 8 mA, a pulse duration of 100 microseconds-200 microseconds, and a frequency of approximately 20 Hz-50 Hz. In still other embodiments, the current can be approximately 4 mA to 6 mA, and more particularly approximately around 5 mA. The waveforms of any of the foregoing embodiments can have a voltage of approximately: 0.25 V to 5.0 V in many applications; 0.5 V to 3.5 V in more specific applications; 2.0 V to 3.5 V in still more specific applications; and 3.0 V in a particular application. Additionally, the pulse duration can be in the range of 90-180 microseconds. The stimulus can be applied for a period of 0.5 hour-4.0 hours, and in many applications the therapy is applied for a period of approximately 0.5 hour-1.5 hours. In other embodiments, the stimulation can be applied continuously, or only during waking periods but not sleeping periods. Examples of specific stimulation protocols for use with an electrode array at an epidural stimulation site over the precentral gyrus are as follows:
- An electrical stimulus having a current of approximately 0.1 mA to 10 mA, an impedance of 600 to 1000 Ohms, a pulse duration of 160 microseconds, and a frequency of approximately 130 Hz. The therapy is not applied continuously, but rather during 30-60 minute intervals.
- The stimulus has a current of approximately 0.1 mA to 10 mA, a pulse duration of approximately 150-180 microseconds, and a frequency of approximately 25 Hz-31 Hz. The stimulus is applied continuously during waking periods, but it is discontinued during sleeping periods to conserve battery life of the implanted pulse generator.
- The stimulus has a current of approximately 2 mA to 4 mA, a pulse duration of approximately 90 microseconds, and a frequency of approximately 30 Hz. This stimulus is applied continuously during waking and sleeping periods, but it can be discontinued during sleeping periods.
-
FIG. 5 illustrates another aspect of an embodiment of the invention. In many cases of PD, the symptoms are manifested to a greater extent on one side of the body than the other. For example, a patient may have a tremor in both hands, but usually one hand will have a tremor worse than the other hand. In this embodiment, the patient's body is divided into a first side and a second side opposite the first side relative to a medial axis (e.g., right side-left side), and only one side of the cortex is stimulated to treat the disorder on both sides of the body. This embodiment can be carried out by implanting theelectrode array cortex 220. The bilateral effect of the single-side stimulation may be enhanced using monopolar stimulation techniques in which the electrodes are biased with the same polarity. The bilateral effect may be caused by activation of commissural neurons (large pyramidal cells) in the deep portion of layer III of the motor cortex. Subsequent to activation, these neurons can depolarize complimentary cell groups in the contralateral hemisphere via the corpus callosum. - In a specific embodiment, by accurately locating the electrodes over the precentral gyrus using the imaging and
site selection procedures cortex 220 of the patient. This reduces the invasiveness and the risk associated with surgery. -
FIG. 5 also illustrates another embodiment in which anelectrode array 330 a (shown in broken line) is implanted at a site on the ipsilateral hemisphere of the brain relative to the side of the body most affected by the movement disorder. Theelectrode array 330 a can be implanted by itself such that it is the only electrode array. In a different embodiment, however, both of theelectrode arrays electrode array 330 a can have only a single electrode as described above with respect to theelectrode array 330. -
FIG. 6 is a schematic view illustrating embodiments of systems for treating movement disorders in accordance with the invention. The system can include thelinear electrode array 310 coupled to an implantedpulse generator 600 a implanted at a subclavicular location in the patient P. Thegrid electrode array 330 can be substituted for thelinear electrode array 310. In either of these embodiments, alead 322/342 is tunneled between the implantedpulse generator 600 a and the electrode array. In another embodiment, the system has an implanted above-neck pulse generator 600 b that is smaller and configured to be implanted at a location above the neck of the patient P. The above-neck implantedpulse generator 600 b can be planted posteriorly of the ear of the patient P. In each of these embodiments, theelectrode arrays 310 or 330 (not shown inFIG. 6 ) are implanted underneath the scull S of the patient P at an epidural or subdural stimulation site as set forth above. -
FIG. 7 is a flow chart illustrating additional methods for treating movement disorders in accordance with additional embodiments of the invention. In one embodiment, amethod 700 includes asite selection procedure 710 including determining a cortical site related to a movement disorder of an afflicted body part of the patient. In one embodiment, thesite selection procedure 710 includes obtaining a representation of neural activity occurring in the cortex of the patient, and correlating an area of neural activity with the afflicted body part. In a related embodiment, thesite selection procedure 710 can include providing a representation of neural activity in the cortex of the brain of a patient, identifying a neural activation area on the representation considered to be related to a body part of the patient affected by a movement disorder, and selecting the cortical site on the patient by referencing the identified neural activation area to the anatomy of the patient. - In patients having little or no tremor symptoms, a representation of neural activity occurring in the cortex can be obtained or provided by imaging neural activity in the cortex using a neural imaging technique while performing a task related to the affected body part. For example, the representation of neural activity in the cortex can be obtained by imaging cortical neural activity while (a) the patient mentally concentrates on moving the affected body part, (b) the affected body part is moved by the patient, (c) an electrical pulse is applied to the affected body part, and/or (d) another person or device passively moves the affected body part. In other embodiments, obtaining a representation of neural activity in the brain can include collecting data of neural activity in the cortex of the patient related to the affected body part without necessarily generating an image. The collected data can be stored in a memory and processed to generate anatomical coordinates and/or an image of the neural activity.
- The
site selection procedure 710 is expected to increase the efficacy of the stimulation therapy and provide additional benefits. For example, having the patient concentrate on moving the affected body part or actually move the affected body part while imaging the neural activity in the cortex is expected to provide an accurate indication of the area(s) in the cortex where neural activity for controlling the motor function of the affected body part is performed. Similarly, applying an electrical pulse to the affected body part while imaging neural activity in the cortex is expected to provide another accurate indication of where neural activity occurs for controlling the motor function of the affected body part. By providing an accurate indication of the location of neural activity related to the affected body part, themethod 700 is expected to operate at low electrical potentials to reduce unwanted collateral stimulation of neurons and prolong the battery life of an implanted pulse generator. Moreover, such precise location of the electrodes enhances the efficacy of the stimulation procedure because the neurons that are involved in controlling the affected body part are more likely to be stimulated in a controlled manner. - The
method 700 further includes astimulation procedure 720 that involves applying neural stimulation directly to the cortical site. The stimulation procedure can be preceded by implanting an electrode unit proximate to the dura mater at the cortical site. The electrode unit can have a single electrode or an array with a plurality of electrodes as explained above. Thestimulation procedure 720 can include any of the electrical waveforms set forth above. In additional embodiments, the stimulation procedure can include applying an electrical waveform having a frequency of approximately 5-1000 Hz. In more specific embodiments, thestimulation procedure 720 can include applying an electrical waveform having a frequency of approximately 10-60 Hz, and more specifically at a frequency of 20 Hz or 50 Hz. Other examples could be at higher frequencies of 90-150 Hz or in a narrower range of 100-120 Hz. -
FIG. 8 is a flow chart illustrating another method for treating movement disorders in accordance with additional embodiments of the invention. In one embodiment, themethod 800 includes performing acraniotomy 810 to expose a cortical location related to an affected body part. Thecraniotomy 810 can expose subdural or epidural tissue. Themethod 800 further includes atest procedure 820 and amapping procedure 830. Thetest procedure 820 includes applying a test stimulation waveform to a plurality of discrete regions of the cortical location. In one embodiment of thetest procedure 820, a single electrode is moved to different discrete locations of the cortical region exposed by the craniotomy and an electrical pulse is applied to each location separately. In other embodiments, thetest procedure 820 includes implanting an electrode array having a plurality of electrodes such that each electrode is adjacent to a discrete region of the cortical location. This embodiment includes applying the test stimulation waveform separately to one or more of the individual electrodes in different combinations. Both of these embodiments of thetest procedure 820 apply the test stimulation waveform to the discrete regions of the cortical location at separate time periods. Themapping procedure 830 includes (a) verifying the proper electrode location and/or (b) measuring the efficacy of the test stimulation waveforms as they are applied to the different discrete regions of the cortical location. The mapping procedure can occur while the patient is under an anesthetic, and it can also apply electrical pulses at a current that is sufficient to provoke a response. After verifying the electrode location during surgery, themapping procedure 830 can further include monitoring the decrease and/or increase in the tremor of a body part affected by PD as the test waveform is applied to the different discrete regions. Themethod 800 further includes aselection procedure 840 in which one or more of the discrete regions is selected based upon the efficacy of the discrete regions for treating the movement disorder. Theselection procedure 840 accordingly determines which electrode(s) receive electrical pulses for treating the movement disorder. Themethod 800, accordingly, further includes astimulation procedure 850 including applying a therapy stimulation waveform to the selected regions of the cortical location. -
FIG. 9 is a flow chart of anothermethod 900 for treating movement disorders in accordance with another embodiment of the invention. Themethod 900 includes an implantingprocedure 910 in which an electrode is implanted at a cortical stimulation site based upon a standard correlation between cortical neural activity and motor functions in humans. For example, an electrode array can be implanted at a cortical stimulation site based upon the standard correlation between cortical neural activity and motor functions in humans, and in particular the standard location for neural activity in humans for motor control of the affected body part. The implantingprocedure 910 accordingly does not necessarily need to select the stimulation site based upon an image, data or other information to obtain or provide a representation of neural activity in the brain related to the affected body part. Themethod 900 further includes astimulation procedure 920 involving applying electrical stimulation to the cortical location to treat a movement disorder. - From the foregoing, it will be appreciated that specific embodiments of the invention have been described herein for purposes of illustration, but that various modifications may be made without deviating from the spirit and scope of the invention. For example, the leads of the electrode arrays may be coupled to an external pulse generator instead of an implanted pulse generator. In an alternate embodiment, the stimulation site can be selected at an area of the cortex that is not normally associated with the function of the body part(s) affected by the movement disorder (e.g., non-homologous regions). This embodiment accordingly places the electrodes at other neurofunctional areas that control other movement and/or speech functions. In still other embodiments, electrode arrays having different configurations of electrodes can be implanted on opposing hemispheres of the cortex. Furthermore, in an additional embodiment, transcutaneous magnetic stimulation can be applied to the selected stimulation site before implanting the electrodes to estimate the response and refine the location of the stimulation site. For example, a stimulation site can be selected using an imaging modality (e.g., MRI, fMFI, etc.) and/or externally estimating the site according to the normal location for neural activity associated with the movement disorder, and then transcutaneous magnetic stimulation can be applied at the stimulation site and/or neighboring areas before implanting the electrode. The precise location for the stimulation site can then be modified according to the results of the transcutaneous magnetic stimulation in a manner similar to the
mapping procedure 830 described above. Accordingly, the invention is not limited except as by the appended claims.
Claims (7)
1. A method of improving symptoms associated with a movement disorder comprising:
selecting a stimulation site based upon a patient's symptomatology, wherein the symptomatology of gait disturbance biases the selecting towards interhemispheric fissure along the precentral gyrus and/or postcentral gyrus and the symptomotalogy of speech disturbance biases the selecting towards the Sylvian fissure along the precentral gyrus and/or postcentral gyrus;
positioning at least one electrode device having a plurality of electrical contacts such that at least a first of the plurality of electrical contacts is positioned below the patient's skull and on the dura over the stimulation site; and
applying electrical signals to the electrical contacts to stimulate the stimulation site such that at least one symptom associated with the movement disorder is improved.
2. The method of claim 1 wherein the movement disorder is Parkinson's Disease.
3. The method of claim 1 wherein positioning the electrode comprises positing an array having a plurality of electrodes such that at least one electrode is over the precental gurus and at least one other electrode is over the postcentral gurus of the patient.
4. The method of claim 1 wherein positioning the electrode comprises position an array having a plurality of electrodes over only the precetnral guyrus of the patient.
5. The method of claim 1 further comprising obtaining a representation of neural activity occurring in the cortex of the patient and correlating an area of neural activity with an afflicted body part to further select the stimulation site.
6. The method of claim 1 wherein a function that is affected by the movement disorder is gait and the superior-inferior location along the precentral gyrus comprises a location closer to the interhemispheric fissure than the Sylvian fissure.
7. The method of claim 1 wherein a function that is affected by the movement disorder is speech and the superior-inferior location along the precentral gyrus comprises a location closer to the Sylvian fissure than the interhemispheric fissure.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/100,646 US20110208263A1 (en) | 2001-03-08 | 2011-05-04 | System and method for treating parkinson's disease and other movement disorders |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/802,808 US7010351B2 (en) | 2000-07-13 | 2001-03-08 | Methods and apparatus for effectuating a lasting change in a neural-function of a patient |
US43207302P | 2002-12-09 | 2002-12-09 | |
US10/731,731 US7299096B2 (en) | 2001-03-08 | 2003-12-09 | System and method for treating Parkinson's Disease and other movement disorders |
US11/867,654 US7962218B2 (en) | 2001-03-08 | 2007-10-04 | System and method for treating Parkinson's Disease and other movement disorders |
US13/100,646 US20110208263A1 (en) | 2001-03-08 | 2011-05-04 | System and method for treating parkinson's disease and other movement disorders |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/867,654 Continuation US7962218B2 (en) | 2001-03-08 | 2007-10-04 | System and method for treating Parkinson's Disease and other movement disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
US20110208263A1 true US20110208263A1 (en) | 2011-08-25 |
Family
ID=46300488
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/731,731 Expired - Lifetime US7299096B2 (en) | 2001-03-08 | 2003-12-09 | System and method for treating Parkinson's Disease and other movement disorders |
US11/867,654 Expired - Fee Related US7962218B2 (en) | 2001-03-08 | 2007-10-04 | System and method for treating Parkinson's Disease and other movement disorders |
US13/100,646 Abandoned US20110208263A1 (en) | 2001-03-08 | 2011-05-04 | System and method for treating parkinson's disease and other movement disorders |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/731,731 Expired - Lifetime US7299096B2 (en) | 2001-03-08 | 2003-12-09 | System and method for treating Parkinson's Disease and other movement disorders |
US11/867,654 Expired - Fee Related US7962218B2 (en) | 2001-03-08 | 2007-10-04 | System and method for treating Parkinson's Disease and other movement disorders |
Country Status (1)
Country | Link |
---|---|
US (3) | US7299096B2 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9533155B2 (en) | 2014-08-15 | 2017-01-03 | Axonics Modulation Technologies, Inc. | Methods for determining neurostimulation electrode configurations based on neural localization |
US9555246B2 (en) | 2014-08-15 | 2017-01-31 | Axonics Modulation Technologies, Inc. | Electromyographic lead positioning and stimulation titration in a nerve stimulation system for treatment of overactive bladder |
US10092762B2 (en) | 2014-08-15 | 2018-10-09 | Axonics Modulation Technologies, Inc. | Integrated electromyographic clinician programmer for use with an implantable neurostimulator |
WO2020255142A3 (en) * | 2019-06-18 | 2021-03-04 | Eeg-Sense Ltd. | Method and system for measuring eeg signals |
US11439829B2 (en) | 2019-05-24 | 2022-09-13 | Axonics, Inc. | Clinician programmer methods and systems for maintaining target operating temperatures |
US11848090B2 (en) | 2019-05-24 | 2023-12-19 | Axonics, Inc. | Trainer for a neurostimulator programmer and associated methods of use with a neurostimulation system |
Families Citing this family (169)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9415222B2 (en) * | 1998-08-05 | 2016-08-16 | Cyberonics, Inc. | Monitoring an epilepsy disease state with a supervisory module |
US9320900B2 (en) | 1998-08-05 | 2016-04-26 | Cyberonics, Inc. | Methods and systems for determining subject-specific parameters for a neuromodulation therapy |
US9375573B2 (en) * | 1998-08-05 | 2016-06-28 | Cyberonics, Inc. | Systems and methods for monitoring a patient's neurological disease state |
US7209787B2 (en) | 1998-08-05 | 2007-04-24 | Bioneuronics Corporation | Apparatus and method for closed-loop intracranial stimulation for optimal control of neurological disease |
US9042988B2 (en) | 1998-08-05 | 2015-05-26 | Cyberonics, Inc. | Closed-loop vagus nerve stimulation |
US7747325B2 (en) | 1998-08-05 | 2010-06-29 | Neurovista Corporation | Systems and methods for monitoring a patient's neurological disease state |
US8762065B2 (en) | 1998-08-05 | 2014-06-24 | Cyberonics, Inc. | Closed-loop feedback-driven neuromodulation |
US7062330B1 (en) * | 1998-10-26 | 2006-06-13 | Boveja Birinder R | Electrical stimulation adjunct (Add-ON) therapy for urinary incontinence and urological disorders using implanted lead stimulus-receiver and an external pulse generator |
US20060217782A1 (en) * | 1998-10-26 | 2006-09-28 | Boveja Birinder R | Method and system for cortical stimulation to provide adjunct (ADD-ON) therapy for stroke, tinnitus and other medical disorders using implantable and external components |
US7756584B2 (en) | 2000-07-13 | 2010-07-13 | Advanced Neuromodulation Systems, Inc. | Methods and apparatus for effectuating a lasting change in a neural-function of a patient |
US7831305B2 (en) | 2001-10-15 | 2010-11-09 | Advanced Neuromodulation Systems, Inc. | Neural stimulation system and method responsive to collateral neural activity |
US7672730B2 (en) * | 2001-03-08 | 2010-03-02 | Advanced Neuromodulation Systems, Inc. | Methods and apparatus for effectuating a lasting change in a neural-function of a patient |
US7024247B2 (en) | 2001-10-15 | 2006-04-04 | Northstar Neuroscience, Inc. | Systems and methods for reducing the likelihood of inducing collateral neural activity during neural stimulation threshold test procedures |
US7305268B2 (en) | 2000-07-13 | 2007-12-04 | Northstar Neurscience, Inc. | Systems and methods for automatically optimizing stimulus parameters and electrode configurations for neuro-stimulators |
US7010351B2 (en) | 2000-07-13 | 2006-03-07 | Northstar Neuroscience, Inc. | Methods and apparatus for effectuating a lasting change in a neural-function of a patient |
US7221981B2 (en) | 2002-03-28 | 2007-05-22 | Northstar Neuroscience, Inc. | Electrode geometries for efficient neural stimulation |
US7236830B2 (en) | 2002-12-10 | 2007-06-26 | Northstar Neuroscience, Inc. | Systems and methods for enhancing or optimizing neural stimulation therapy for treating symptoms of Parkinson's disease and/or other movement disorders |
US20050075680A1 (en) | 2003-04-18 | 2005-04-07 | Lowry David Warren | Methods and systems for intracranial neurostimulation and/or sensing |
AU2003297735A1 (en) | 2002-12-09 | 2004-06-30 | Medtronic, Inc. | Modular implantable medical device |
US7596408B2 (en) | 2002-12-09 | 2009-09-29 | Medtronic, Inc. | Implantable medical device with anti-infection agent |
US20050004637A1 (en) * | 2003-05-16 | 2005-01-06 | Ruchika Singhal | Explantation of implantable medical device |
US7263401B2 (en) | 2003-05-16 | 2007-08-28 | Medtronic, Inc. | Implantable medical device with a nonhermetic battery |
WO2005011805A2 (en) | 2003-08-01 | 2005-02-10 | Northstar Neuroscience, Inc. | Apparatus and methods for applying neural stimulation to a patient |
EP1694403A2 (en) * | 2003-11-20 | 2006-08-30 | Advanced Neuromodulation Systems, Inc. | Electrical stimulation system, lead, and method providing reduced neuroplasticity effects |
US9050469B1 (en) | 2003-11-26 | 2015-06-09 | Flint Hills Scientific, Llc | Method and system for logging quantitative seizure information and assessing efficacy of therapy using cardiac signals |
US7596399B2 (en) * | 2004-04-29 | 2009-09-29 | Medtronic, Inc | Implantation of implantable medical device |
US20050245984A1 (en) | 2004-04-30 | 2005-11-03 | Medtronic, Inc. | Implantable medical device with lubricious material |
US7346382B2 (en) | 2004-07-07 | 2008-03-18 | The Cleveland Clinic Foundation | Brain stimulation models, systems, devices, and methods |
AU2005275209B2 (en) | 2004-07-15 | 2010-06-24 | Advanced Neuromodulation Systems, Inc. | Systems and methods for enhancing or affecting neural stimulation efficiency and/or efficacy |
US7565200B2 (en) | 2004-11-12 | 2009-07-21 | Advanced Neuromodulation Systems, Inc. | Systems and methods for selecting stimulation sites and applying treatment, including treatment of symptoms of Parkinson's disease, other movement disorders, and/or drug side effects |
US20060129056A1 (en) * | 2004-12-10 | 2006-06-15 | Washington University | Electrocorticography telemitter |
US8214035B2 (en) * | 2004-12-17 | 2012-07-03 | Medtronic, Inc. | System and method for utilizing brain state information to modulate cardiac therapy |
US20070239060A1 (en) * | 2004-12-17 | 2007-10-11 | Medtronic, Inc. | System and method for regulating cardiac triggered therapy to the brain |
US8209019B2 (en) | 2004-12-17 | 2012-06-26 | Medtronic, Inc. | System and method for utilizing brain state information to modulate cardiac therapy |
US8209009B2 (en) * | 2004-12-17 | 2012-06-26 | Medtronic, Inc. | System and method for segmenting a cardiac signal based on brain stimulation |
US8112153B2 (en) * | 2004-12-17 | 2012-02-07 | Medtronic, Inc. | System and method for monitoring or treating nervous system disorders |
US8112148B2 (en) * | 2004-12-17 | 2012-02-07 | Medtronic, Inc. | System and method for monitoring cardiac signal activity in patients with nervous system disorders |
US8108038B2 (en) * | 2004-12-17 | 2012-01-31 | Medtronic, Inc. | System and method for segmenting a cardiac signal based on brain activity |
WO2006066098A1 (en) | 2004-12-17 | 2006-06-22 | Medtronic, Inc. | System and method for monitoring or treating nervous system disorders |
US8108046B2 (en) | 2004-12-17 | 2012-01-31 | Medtronic, Inc. | System and method for using cardiac events to trigger therapy for treating nervous system disorders |
US8485979B2 (en) * | 2004-12-17 | 2013-07-16 | Medtronic, Inc. | System and method for monitoring or treating nervous system disorders |
US9314633B2 (en) | 2008-01-25 | 2016-04-19 | Cyberonics, Inc. | Contingent cardio-protection for epilepsy patients |
US8565867B2 (en) | 2005-01-28 | 2013-10-22 | Cyberonics, Inc. | Changeable electrode polarity stimulation by an implantable medical device |
US8260426B2 (en) | 2008-01-25 | 2012-09-04 | Cyberonics, Inc. | Method, apparatus and system for bipolar charge utilization during stimulation by an implantable medical device |
US7729773B2 (en) | 2005-10-19 | 2010-06-01 | Advanced Neuromodualation Systems, Inc. | Neural stimulation and optical monitoring systems and methods |
US8929991B2 (en) | 2005-10-19 | 2015-01-06 | Advanced Neuromodulation Systems, Inc. | Methods for establishing parameters for neural stimulation, including via performance of working memory tasks, and associated kits |
US8725243B2 (en) | 2005-12-28 | 2014-05-13 | Cyberonics, Inc. | Methods and systems for recommending an appropriate pharmacological treatment to a patient for managing epilepsy and other neurological disorders |
US8868172B2 (en) | 2005-12-28 | 2014-10-21 | Cyberonics, Inc. | Methods and systems for recommending an appropriate action to a patient for managing epilepsy and other neurological disorders |
US7996079B2 (en) | 2006-01-24 | 2011-08-09 | Cyberonics, Inc. | Input response override for an implantable medical device |
US8190251B2 (en) * | 2006-03-24 | 2012-05-29 | Medtronic, Inc. | Method and apparatus for the treatment of movement disorders |
BRPI0709844A2 (en) | 2006-03-29 | 2011-07-26 | Catholic Healthcare West | Cranial nerve micrograde electrical stimulation for the treatment of medical conditions |
US7764989B2 (en) * | 2006-04-21 | 2010-07-27 | Medtronic, Inc. | Method and apparatus for detection of nervous system disorders |
US7761146B2 (en) * | 2006-04-21 | 2010-07-20 | Medtronic, Inc. | Method and apparatus for detection of nervous system disorders |
US7761145B2 (en) * | 2006-04-21 | 2010-07-20 | Medtronic, Inc. | Method and apparatus for detection of nervous system disorders |
US20070249953A1 (en) * | 2006-04-21 | 2007-10-25 | Medtronic, Inc. | Method and apparatus for detection of nervous system disorders |
US20070249956A1 (en) * | 2006-04-21 | 2007-10-25 | Medtronic, Inc. | Method and apparatus for detection of nervous system disorders |
US8165683B2 (en) | 2006-04-21 | 2012-04-24 | Medtronic, Inc. | Method and apparatus for detection of nervous system disorders |
US9084901B2 (en) | 2006-04-28 | 2015-07-21 | Medtronic, Inc. | Cranial implant |
US7962220B2 (en) | 2006-04-28 | 2011-06-14 | Cyberonics, Inc. | Compensation reduction in tissue stimulation therapy |
US7869885B2 (en) | 2006-04-28 | 2011-01-11 | Cyberonics, Inc | Threshold optimization for tissue stimulation therapy |
EP2034885A4 (en) * | 2006-06-23 | 2010-12-01 | Neurovista Corp | Minimally invasive monitoring systems and methods |
US7869867B2 (en) * | 2006-10-27 | 2011-01-11 | Cyberonics, Inc. | Implantable neurostimulator with refractory stimulation |
US8295934B2 (en) | 2006-11-14 | 2012-10-23 | Neurovista Corporation | Systems and methods of reducing artifact in neurological stimulation systems |
WO2008092133A2 (en) * | 2007-01-25 | 2008-07-31 | Neurovista Corporation | Methods and systems for measuring a subject's susceptibility to a seizure |
US9898656B2 (en) * | 2007-01-25 | 2018-02-20 | Cyberonics, Inc. | Systems and methods for identifying a contra-ictal condition in a subject |
JP2010519949A (en) * | 2007-03-02 | 2010-06-10 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | Electrode system for deep brain stimulation |
US8036736B2 (en) * | 2007-03-21 | 2011-10-11 | Neuro Vista Corporation | Implantable systems and methods for identifying a contra-ictal condition in a subject |
US20080255582A1 (en) * | 2007-04-11 | 2008-10-16 | Harris John F | Methods and Template Assembly for Implanting an Electrode Array in a Patient |
US8000788B2 (en) * | 2007-04-27 | 2011-08-16 | Medtronic, Inc. | Implantable medical device for treating neurological conditions including ECG sensing |
US7974701B2 (en) | 2007-04-27 | 2011-07-05 | Cyberonics, Inc. | Dosing limitation for an implantable medical device |
US9788744B2 (en) * | 2007-07-27 | 2017-10-17 | Cyberonics, Inc. | Systems for monitoring brain activity and patient advisory device |
BRPI0817271A2 (en) * | 2007-09-26 | 2015-06-16 | Univ Duke | Method of treating Parkinson's disease and other related disorders |
US20090105786A1 (en) * | 2007-10-22 | 2009-04-23 | University Of Washington | Method and device for strengthening synaptic connections |
JP4488057B2 (en) * | 2007-11-09 | 2010-06-23 | セイコーエプソン株式会社 | Active matrix device, electro-optical display device, and electronic apparatus |
US9089707B2 (en) | 2008-07-02 | 2015-07-28 | The Board Of Regents, The University Of Texas System | Systems, methods and devices for paired plasticity |
US8457757B2 (en) * | 2007-11-26 | 2013-06-04 | Micro Transponder, Inc. | Implantable transponder systems and methods |
US9259591B2 (en) | 2007-12-28 | 2016-02-16 | Cyberonics, Inc. | Housing for an implantable medical device |
US20090171168A1 (en) | 2007-12-28 | 2009-07-02 | Leyde Kent W | Systems and Method for Recording Clinical Manifestations of a Seizure |
US8571643B2 (en) | 2010-09-16 | 2013-10-29 | Flint Hills Scientific, Llc | Detecting or validating a detection of a state change from a template of heart rate derivative shape or heart beat wave complex |
US8382667B2 (en) | 2010-10-01 | 2013-02-26 | Flint Hills Scientific, Llc | Detecting, quantifying, and/or classifying seizures using multimodal data |
US8337404B2 (en) | 2010-10-01 | 2012-12-25 | Flint Hills Scientific, Llc | Detecting, quantifying, and/or classifying seizures using multimodal data |
US9220889B2 (en) | 2008-02-11 | 2015-12-29 | Intelect Medical, Inc. | Directional electrode devices with locating features |
US8019440B2 (en) | 2008-02-12 | 2011-09-13 | Intelect Medical, Inc. | Directional lead assembly |
US8204603B2 (en) | 2008-04-25 | 2012-06-19 | Cyberonics, Inc. | Blocking exogenous action potentials by an implantable medical device |
US9272153B2 (en) | 2008-05-15 | 2016-03-01 | Boston Scientific Neuromodulation Corporation | VOA generation system and method using a fiber specific analysis |
KR101048084B1 (en) * | 2008-07-28 | 2011-07-11 | 한양대학교 산학협력단 | Noninvasive Cerebral Implants |
ES2462759T3 (en) | 2008-10-01 | 2014-05-26 | Sherwin Hua | System for pedicle screw stabilization guided by column vertebrae wire |
US8457747B2 (en) | 2008-10-20 | 2013-06-04 | Cyberonics, Inc. | Neurostimulation with signal duration determined by a cardiac cycle |
US8417344B2 (en) | 2008-10-24 | 2013-04-09 | Cyberonics, Inc. | Dynamic cranial nerve stimulation based on brain state determination from cardiac data |
US9393432B2 (en) | 2008-10-31 | 2016-07-19 | Medtronic, Inc. | Non-hermetic direct current interconnect |
US8849390B2 (en) | 2008-12-29 | 2014-09-30 | Cyberonics, Inc. | Processing for multi-channel signals |
US8588933B2 (en) | 2009-01-09 | 2013-11-19 | Cyberonics, Inc. | Medical lead termination sleeve for implantable medical devices |
US20100191304A1 (en) | 2009-01-23 | 2010-07-29 | Scott Timothy L | Implantable Medical Device for Providing Chronic Condition Therapy and Acute Condition Therapy Using Vagus Nerve Stimulation |
US8792972B2 (en) * | 2009-02-05 | 2014-07-29 | Alpha Omega Engineering Ltd. | Real-time methods and systems for mapping a target region in the brain during surgery |
US8827912B2 (en) | 2009-04-24 | 2014-09-09 | Cyberonics, Inc. | Methods and systems for detecting epileptic events using NNXX, optionally with nonlinear analysis parameters |
US8239028B2 (en) | 2009-04-24 | 2012-08-07 | Cyberonics, Inc. | Use of cardiac parameters in methods and systems for treating a chronic medical condition |
US8786624B2 (en) | 2009-06-02 | 2014-07-22 | Cyberonics, Inc. | Processing for multi-channel signals |
BRPI1015422A2 (en) | 2009-07-30 | 2016-04-19 | Sapiens Steering Brain Stimulation Bv | deep brain stimulation system, methods for determining amplitudes, for applying a spatial distribution of amplitudes and computer program product. |
EP2470258B1 (en) | 2009-08-27 | 2017-03-15 | The Cleveland Clinic Foundation | System and method to estimate region of tissue activation |
WO2011068997A1 (en) | 2009-12-02 | 2011-06-09 | The Cleveland Clinic Foundation | Reversing cognitive-motor impairments in patients having a neuro-degenerative disease using a computational modeling approach to deep brain stimulation programming |
KR20130004253A (en) | 2009-12-21 | 2013-01-09 | 셔윈 화 | Insertion of medical devices through non-orthogonal and orthogonal trajectories within the cranium and methods of using |
US9643019B2 (en) | 2010-02-12 | 2017-05-09 | Cyberonics, Inc. | Neurological monitoring and alerts |
KR20130004487A (en) | 2010-03-01 | 2013-01-10 | 뉴로넥서스 테크놀러지스, 인크. | Method and system for determining settings for deep brain stimulation |
US8649871B2 (en) | 2010-04-29 | 2014-02-11 | Cyberonics, Inc. | Validity test adaptive constraint modification for cardiac data used for detection of state changes |
US8562536B2 (en) | 2010-04-29 | 2013-10-22 | Flint Hills Scientific, Llc | Algorithm for detecting a seizure from cardiac data |
US8831732B2 (en) | 2010-04-29 | 2014-09-09 | Cyberonics, Inc. | Method, apparatus and system for validating and quantifying cardiac beat data quality |
EP2580710B1 (en) | 2010-06-14 | 2016-11-09 | Boston Scientific Neuromodulation Corporation | Programming interface for spinal cord neuromodulation |
US8679009B2 (en) | 2010-06-15 | 2014-03-25 | Flint Hills Scientific, Llc | Systems approach to comorbidity assessment |
US8641646B2 (en) | 2010-07-30 | 2014-02-04 | Cyberonics, Inc. | Seizure detection using coordinate data |
US8562523B2 (en) | 2011-03-04 | 2013-10-22 | Flint Hills Scientific, Llc | Detecting, assessing and managing extreme epileptic events |
US8684921B2 (en) | 2010-10-01 | 2014-04-01 | Flint Hills Scientific Llc | Detecting, assessing and managing epilepsy using a multi-variate, metric-based classification analysis |
US8562524B2 (en) | 2011-03-04 | 2013-10-22 | Flint Hills Scientific, Llc | Detecting, assessing and managing a risk of death in epilepsy |
CA2815507C (en) * | 2010-10-19 | 2021-07-20 | The Cleveland Clinic Foundation | Methods for identifying target stimulation regions associated with therapeutic and non-therapeutic clinical outcomes for neural stimulation |
EP4201475A1 (en) | 2011-01-03 | 2023-06-28 | The Regents of the University of California | High density epidural stimulation for facilitation of locomotion, posture, voluntary movement, and recovery of autonomic, sexual, vasomotor, and cognitive function after neurological injury |
US20140031605A1 (en) * | 2011-02-02 | 2014-01-30 | Universite Laval | Method and Use of Peripheral Theta-Burst Stimulation (PTBS) for Improving Motor Impairment |
US9504390B2 (en) | 2011-03-04 | 2016-11-29 | Globalfoundries Inc. | Detecting, assessing and managing a risk of death in epilepsy |
AU2012230699A1 (en) | 2011-03-24 | 2013-05-23 | California Institute Of Technology | Neurostimulator |
EP2691899A2 (en) | 2011-03-29 | 2014-02-05 | Boston Scientific Neuromodulation Corporation | System and method for leadwire location |
US8725239B2 (en) | 2011-04-25 | 2014-05-13 | Cyberonics, Inc. | Identifying seizures using heart rate decrease |
US9402550B2 (en) | 2011-04-29 | 2016-08-02 | Cybertronics, Inc. | Dynamic heart rate threshold for neurological event detection |
US9592389B2 (en) | 2011-05-27 | 2017-03-14 | Boston Scientific Neuromodulation Corporation | Visualization of relevant stimulation leadwire electrodes relative to selected stimulation information |
US9925382B2 (en) | 2011-08-09 | 2018-03-27 | Boston Scientific Neuromodulation Corporation | Systems and methods for stimulation-related volume analysis, creation, and sharing |
US10206591B2 (en) | 2011-10-14 | 2019-02-19 | Flint Hills Scientific, Llc | Seizure detection methods, apparatus, and systems using an autoregression algorithm |
CA2856202C (en) | 2011-11-11 | 2020-02-18 | Victor Reggie EDGERTON | Non invasive neuromodulation device for enabling recovery of motor, sensory, autonomic, sexual, vasomotor and cognitive function |
US10092750B2 (en) | 2011-11-11 | 2018-10-09 | Neuroenabling Technologies, Inc. | Transcutaneous neuromodulation system and methods of using same |
US10448839B2 (en) | 2012-04-23 | 2019-10-22 | Livanova Usa, Inc. | Methods, systems and apparatuses for detecting increased risk of sudden death |
CN102764119A (en) * | 2012-07-20 | 2012-11-07 | 中国科学院深圳先进技术研究院 | Electrode array |
EP2879757B1 (en) | 2012-08-04 | 2019-06-26 | Boston Scientific Neuromodulation Corporation | Systems and methods for storing and transferring registration, atlas, and lead information between medical devices |
EP2890454B1 (en) | 2012-08-28 | 2017-11-08 | Boston Scientific Neuromodulation Corporation | Point-and-click programming for deep brain stimulation using real-time monopolar review trendlines |
WO2014070290A2 (en) | 2012-11-01 | 2014-05-08 | Boston Scientific Neuromodulation Corporation | Systems and methods for voa model generation and use |
US10220211B2 (en) | 2013-01-22 | 2019-03-05 | Livanova Usa, Inc. | Methods and systems to diagnose depression |
WO2014130571A1 (en) * | 2013-02-19 | 2014-08-28 | The Regents Of The University Of California | Methods of decoding speech from the brain and systems for practicing the same |
WO2015106286A1 (en) | 2014-01-13 | 2015-07-16 | California Institute Of Technology | Neuromodulation systems and methods of using same |
US9959388B2 (en) | 2014-07-24 | 2018-05-01 | Boston Scientific Neuromodulation Corporation | Systems, devices, and methods for providing electrical stimulation therapy feedback |
US10272247B2 (en) | 2014-07-30 | 2019-04-30 | Boston Scientific Neuromodulation Corporation | Systems and methods for stimulation-related volume analysis, creation, and sharing with integrated surgical planning and stimulation programming |
US10265528B2 (en) | 2014-07-30 | 2019-04-23 | Boston Scientific Neuromodulation Corporation | Systems and methods for electrical stimulation-related patient population volume analysis and use |
WO2016057544A1 (en) | 2014-10-07 | 2016-04-14 | Boston Scientific Neuromodulation Corporation | Systems, devices, and methods for electrical stimulation using feedback to adjust stimulation parameters |
US20160175586A1 (en) * | 2014-10-10 | 2016-06-23 | Neurorecovery Technologies, Inc. | Epidural stimulation for facilitation of locomotion, posture, voluntary movement, and recovery of autonomic, sexual, vasomotor, and cognitive function after neurological injury |
US10780283B2 (en) | 2015-05-26 | 2020-09-22 | Boston Scientific Neuromodulation Corporation | Systems and methods for analyzing electrical stimulation and selecting or manipulating volumes of activation |
EP3268082B1 (en) | 2015-05-26 | 2019-04-17 | Boston Scientific Neuromodulation Corporation | Systems and methods for analyzing electrical stimulation and selecting or manipulating volumes of activation |
EP3280490B1 (en) | 2015-06-29 | 2021-09-01 | Boston Scientific Neuromodulation Corporation | Systems for selecting stimulation parameters based on stimulation target region, effects, or side effects |
EP3280491B1 (en) | 2015-06-29 | 2023-03-01 | Boston Scientific Neuromodulation Corporation | Systems for selecting stimulation parameters by targeting and steering |
WO2017062378A1 (en) | 2015-10-09 | 2017-04-13 | Boston Scientific Neuromodulation Corporation | System and methods for clinical effects mapping for directional stimulations leads |
US10716942B2 (en) | 2016-04-25 | 2020-07-21 | Boston Scientific Neuromodulation Corporation | System and methods for directional steering of electrical stimulation |
AU2017281934B2 (en) | 2016-06-24 | 2019-11-14 | Boston Scientific Neuromodulation Corporation | Systems and methods for visual analytics of clinical effects |
EP3487400A4 (en) * | 2016-07-22 | 2020-01-08 | The Trustees of the University of Pennsylvania | Method and apparatus for improving cognitive performance through cortical stimulation |
WO2018044881A1 (en) | 2016-09-02 | 2018-03-08 | Boston Scientific Neuromodulation Corporation | Systems and methods for visualizing and directing stimulation of neural elements |
US10780282B2 (en) | 2016-09-20 | 2020-09-22 | Boston Scientific Neuromodulation Corporation | Systems and methods for steering electrical stimulation of patient tissue and determining stimulation parameters |
CN109803719B (en) | 2016-10-14 | 2023-05-26 | 波士顿科学神经调制公司 | System and method for closed loop determination of stimulation parameter settings for an electrical simulation system |
JP6834005B2 (en) | 2017-01-03 | 2021-02-24 | ボストン サイエンティフィック ニューロモデュレイション コーポレイション | Systems and methods for selecting MRI-matched stimulus parameters |
ES2821752T3 (en) | 2017-01-10 | 2021-04-27 | Boston Scient Neuromodulation Corp | Systems and procedures for creating stimulation programs based on user-defined areas or volumes |
US10625082B2 (en) | 2017-03-15 | 2020-04-21 | Boston Scientific Neuromodulation Corporation | Visualization of deep brain stimulation efficacy |
WO2018187090A1 (en) | 2017-04-03 | 2018-10-11 | Boston Scientific Neuromodulation Corporation | Systems and methods for estimating a volume of activation using a compressed database of threshold values |
EP3974021B1 (en) | 2017-06-30 | 2023-06-14 | ONWARD Medical N.V. | A system for neuromodulation |
EP3651849B1 (en) | 2017-07-14 | 2023-05-31 | Boston Scientific Neuromodulation Corporation | Estimating clinical effects of electrical stimulation |
EP3634569A1 (en) | 2017-08-15 | 2020-04-15 | Boston Scientific Neuromodulation Corporation | Systems and methods for controlling electrical stimulation using multiple stimulation fields |
WO2019060298A1 (en) | 2017-09-19 | 2019-03-28 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement |
US11717686B2 (en) | 2017-12-04 | 2023-08-08 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to facilitate learning and performance |
US11478603B2 (en) | 2017-12-31 | 2022-10-25 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to enhance emotional response |
US11364361B2 (en) | 2018-04-20 | 2022-06-21 | Neuroenhancement Lab, LLC | System and method for inducing sleep by transplanting mental states |
US11285329B2 (en) | 2018-04-27 | 2022-03-29 | Boston Scientific Neuromodulation Corporation | Systems and methods for visualizing and programming electrical stimulation |
EP3784331B1 (en) | 2018-04-27 | 2023-01-18 | Boston Scientific Neuromodulation Corporation | Multi-mode electrical stimulation systems and methods of making and using |
CN112867532A (en) | 2018-06-01 | 2021-05-28 | 艾奥华大学研究基金会 | Transdural electrode device for stimulating the spinal cord |
WO2020056418A1 (en) | 2018-09-14 | 2020-03-19 | Neuroenhancement Lab, LLC | System and method of improving sleep |
DE18205821T1 (en) | 2018-11-13 | 2020-12-24 | Gtx Medical B.V. | CONTROL SYSTEM FOR MOTION RECONSTRUCTION AND / OR RECOVERY FOR A PATIENT |
EP3653260A1 (en) | 2018-11-13 | 2020-05-20 | GTX medical B.V. | Sensor in clothing of limbs or footwear |
EP3695878B1 (en) | 2019-02-12 | 2023-04-19 | ONWARD Medical N.V. | A system for neuromodulation |
US11160580B2 (en) | 2019-04-24 | 2021-11-02 | Spine23 Inc. | Systems and methods for pedicle screw stabilization of spinal vertebrae |
EP3827871A1 (en) | 2019-11-27 | 2021-06-02 | ONWARD Medical B.V. | Neuromodulation system |
Citations (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3650276A (en) * | 1969-03-26 | 1972-03-21 | Inst Demedicina Si Farmacie | Method and apparatus, including a flexible electrode, for the electric neurostimulation of the neurogenic bladder |
US4140133A (en) * | 1977-04-26 | 1979-02-20 | Moskovsky Oblastnoi Nauchno-Issledovatelsky Institut Akusherstva I Ginekolog Ii | Device for pulse current action on central nervous system |
US4245645A (en) * | 1977-09-28 | 1981-01-20 | Arseneault Pierre Michel | Self-locking cerebral electrical probe |
US4308868A (en) * | 1980-05-27 | 1982-01-05 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Implantable electrical device |
US4328813A (en) * | 1980-10-20 | 1982-05-11 | Medtronic, Inc. | Brain lead anchoring system |
US4431000A (en) * | 1978-11-29 | 1984-02-14 | Gatron Corporation | Transcutaneous nerve stimulator with pseusorandom pulse generator |
US4590946A (en) * | 1984-06-14 | 1986-05-27 | Biomed Concepts, Inc. | Surgically implantable electrode for nerve bundles |
US4646744A (en) * | 1984-06-29 | 1987-03-03 | Zion Foundation | Method and treatment with transcranially applied electrical signals |
US4903702A (en) * | 1988-10-17 | 1990-02-27 | Ad-Tech Medical Instrument Corporation | Brain-contact for sensing epileptogenic foci with improved accuracy |
US5002053A (en) * | 1989-04-21 | 1991-03-26 | University Of Arkansas | Method of and device for inducing locomotion by electrical stimulation of the spinal cord |
US5092835A (en) * | 1990-07-06 | 1992-03-03 | Schurig Janet L S | Brain and nerve healing power apparatus and method |
US5184620A (en) * | 1991-12-26 | 1993-02-09 | Marquette Electronics, Inc. | Method of using a multiple electrode pad assembly |
US5193540A (en) * | 1991-12-18 | 1993-03-16 | Alfred E. Mann Foundation For Scientific Research | Structure and method of manufacture of an implantable microstimulator |
US5282468A (en) * | 1990-06-07 | 1994-02-01 | Medtronic, Inc. | Implantable neural electrode |
US5299569A (en) * | 1991-05-03 | 1994-04-05 | Cyberonics, Inc. | Treatment of neuropsychiatric disorders by nerve stimulation |
US5304206A (en) * | 1991-11-18 | 1994-04-19 | Cyberonics, Inc. | Activation techniques for implantable medical device |
US5303705A (en) * | 1992-05-01 | 1994-04-19 | Nenov Valeriy I | Evoked 23NA MR imaging of sodium currents in the brain |
US5314458A (en) * | 1990-06-01 | 1994-05-24 | University Of Michigan | Single channel microstimulator |
US5405375A (en) * | 1994-01-21 | 1995-04-11 | Incontrol, Inc. | Combined mapping, pacing, and defibrillating catheter |
US5406957A (en) * | 1992-02-05 | 1995-04-18 | Tansey; Michael A. | Electroencephalic neurofeedback apparatus for training and tracking of cognitive states |
US5411540A (en) * | 1993-06-03 | 1995-05-02 | Massachusetts Institute Of Technology | Method and apparatus for preferential neuron stimulation |
US5417719A (en) * | 1993-08-25 | 1995-05-23 | Medtronic, Inc. | Method of using a spinal cord stimulation lead |
US5591216A (en) * | 1995-05-19 | 1997-01-07 | Medtronic, Inc. | Method for treatment of sleep apnea by electrical stimulation |
US5593432A (en) * | 1993-06-23 | 1997-01-14 | Neuroware Therapy International, Inc. | Method for neurostimulation for pain alleviation |
US5601611A (en) * | 1994-08-05 | 1997-02-11 | Ventritex, Inc. | Optical blood flow measurement apparatus and method and implantable defibrillator incorporating same |
US5611350A (en) * | 1996-02-08 | 1997-03-18 | John; Michael S. | Method and apparatus for facilitating recovery of patients in deep coma |
US5618531A (en) * | 1990-10-19 | 1997-04-08 | New York University | Method for increasing the viability of cells which are administered to the brain or spinal cord |
US5707334A (en) * | 1995-08-21 | 1998-01-13 | Young; Robert B. | Method of treating amygdala related transitory disorders |
US5711316A (en) * | 1996-04-30 | 1998-01-27 | Medtronic, Inc. | Method of treating movement disorders by brain infusion |
US5713923A (en) * | 1996-05-13 | 1998-02-03 | Medtronic, Inc. | Techniques for treating epilepsy by brain stimulation and drug infusion |
US5713922A (en) * | 1996-04-25 | 1998-02-03 | Medtronic, Inc. | Techniques for adjusting the locus of excitation of neural tissue in the spinal cord or brain |
US5716377A (en) * | 1996-04-25 | 1998-02-10 | Medtronic, Inc. | Method of treating movement disorders by brain stimulation |
US5722401A (en) * | 1994-10-19 | 1998-03-03 | Cardiac Pathways Corporation | Endocardial mapping and/or ablation catheter probe |
US5735814A (en) * | 1996-04-30 | 1998-04-07 | Medtronic, Inc. | Techniques of treating neurodegenerative disorders by brain infusion |
US5865842A (en) * | 1996-08-29 | 1999-02-02 | Medtronic, Inc. | System and method for anchoring brain stimulation lead or catheter |
US5871517A (en) * | 1997-01-15 | 1999-02-16 | Somatics, Inc. | Convulsive therapy apparatus to stimulate and monitor the extent of therapeutic value of the treatment |
US5885976A (en) * | 1995-05-08 | 1999-03-23 | Sandyk; Reuven | Methods useful for the treatment of neurological and mental disorders related to deficient serotonin neurotransmission and impaired pineal melatonin functions |
US5886769A (en) * | 1998-05-18 | 1999-03-23 | Zolten; A. J. | Method of training and rehabilitating brain function using hemi-lenses |
US5893883A (en) * | 1997-04-30 | 1999-04-13 | Medtronic, Inc. | Portable stimulation screening device for screening therapeutic effect of electrical stimulation on a patient user during normal activities of the patient user |
US6011996A (en) * | 1998-01-20 | 2000-01-04 | Medtronic, Inc | Dual electrode lead and method for brain target localization in functional stereotactic brain surgery |
US6016449A (en) * | 1997-10-27 | 2000-01-18 | Neuropace, Inc. | System for treatment of neurological disorders |
US6018682A (en) * | 1998-04-30 | 2000-01-25 | Medtronic, Inc. | Implantable seizure warning system |
US6021352A (en) * | 1996-06-26 | 2000-02-01 | Medtronic, Inc, | Diagnostic testing methods and apparatus for implantable therapy devices |
US6026326A (en) * | 1997-01-13 | 2000-02-15 | Medtronic, Inc. | Apparatus and method for treating chronic constipation |
US6035236A (en) * | 1998-07-13 | 2000-03-07 | Bionergy Therapeutics, Inc. | Methods and apparatus for electrical microcurrent stimulation therapy |
US6040180A (en) * | 1996-05-23 | 2000-03-21 | Neuralstem Biopharmaceuticals, Ltd. | In vitro generation of differentiated neurons from cultures of mammalian multipotential CNS stem cells |
US6042579A (en) * | 1997-04-30 | 2000-03-28 | Medtronic, Inc. | Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain |
US6052624A (en) * | 1999-01-07 | 2000-04-18 | Advanced Bionics Corporation | Directional programming for implantable electrode arrays |
US6055456A (en) * | 1999-04-29 | 2000-04-25 | Medtronic, Inc. | Single and multi-polar implantable lead for sacral nerve electrical stimulation |
US6176242B1 (en) * | 1999-04-30 | 2001-01-23 | Medtronic Inc | Method of treating manic depression by brain infusion |
US6190893B1 (en) * | 1998-09-18 | 2001-02-20 | Massachusetts Institute Of Technology | Electroactive materials for stimulation of biological activity of bone marrow stromal cells |
US6198958B1 (en) * | 1998-06-11 | 2001-03-06 | Beth Israel Deaconess Medical Center, Inc. | Method and apparatus for monitoring a magnetic resonance image during transcranial magnetic stimulation |
US6205360B1 (en) * | 1995-09-07 | 2001-03-20 | Cochlear Limited | Apparatus and method for automatically determining stimulation parameters |
US6210417B1 (en) * | 1999-04-29 | 2001-04-03 | Medtronic, Inc. | Medical lead positioning and anchoring system |
US6221908B1 (en) * | 1998-03-12 | 2001-04-24 | Scientific Learning Corporation | System for stimulating brain plasticity |
US6339725B1 (en) * | 1996-05-31 | 2002-01-15 | The Board Of Trustees Of Southern Illinois University | Methods of modulating aspects of brain neural plasticity by vagus nerve stimulation |
US6353754B1 (en) * | 2000-04-24 | 2002-03-05 | Neuropace, Inc. | System for the creation of patient specific templates for epileptiform activity detection |
US20020028072A1 (en) * | 2000-09-01 | 2002-03-07 | Ritsuo Kashiyama | Camera having illumination device and control function for same |
US6356792B1 (en) * | 2000-01-20 | 2002-03-12 | Electro Core Technologies, Llc | Skull mounted electrode lead securing assembly |
US6354299B1 (en) * | 1997-10-27 | 2002-03-12 | Neuropace, Inc. | Implantable device for patient communication |
US6366813B1 (en) * | 1998-08-05 | 2002-04-02 | Dilorenzo Daniel J. | Apparatus and method for closed-loop intracranical stimulation for optimal control of neurological disease |
US6375666B1 (en) * | 1999-12-09 | 2002-04-23 | Hans Alois Mische | Methods and devices for treatment of neurological disorders |
US6505075B1 (en) * | 1999-05-29 | 2003-01-07 | Richard L. Weiner | Peripheral nerve stimulation method |
US6507755B1 (en) * | 1998-12-01 | 2003-01-14 | Neurometrix, Inc. | Apparatus and method for stimulating human tissue |
US6529774B1 (en) * | 2000-11-09 | 2003-03-04 | Neuropace, Inc. | Extradural leads, neurostimulator assemblies, and processes of using them for somatosensory and brain stimulation |
US6539263B1 (en) * | 1999-06-11 | 2003-03-25 | Cornell Research Foundation, Inc. | Feedback mechanism for deep brain stimulation |
US6549814B1 (en) * | 2000-06-09 | 2003-04-15 | Juergen Strutz | Blade electrode array for insertion under soft tissue of lateral wall of cochlea |
US20030074032A1 (en) * | 2001-10-15 | 2003-04-17 | Gliner Bradford Evan | Neural stimulation system and method responsive to collateral neural activity |
US20030078633A1 (en) * | 2001-09-28 | 2003-04-24 | Firlik Andrew D. | Methods and implantable apparatus for electrical therapy |
US6684105B2 (en) * | 2001-08-31 | 2004-01-27 | Biocontrol Medical, Ltd. | Treatment of disorders by unidirectional nerve stimulation |
US6687525B2 (en) * | 2000-06-07 | 2004-02-03 | New York University | Method and system for diagnosing and treating thalamocortical dysrhythmia |
US6690974B2 (en) * | 2000-04-05 | 2004-02-10 | Neuropace, Inc. | Stimulation signal generator for an implantable device |
US6708064B2 (en) * | 2000-02-24 | 2004-03-16 | Ali R. Rezai | Modulation of the brain to affect psychiatric disorders |
US20040073270A1 (en) * | 2000-07-13 | 2004-04-15 | Firlik Andrew D. | Methods and apparatus for effectuating a lasting change in a neural-function of a patient |
US6725094B2 (en) * | 1999-03-24 | 2004-04-20 | Lloyd R. Saberski | Apparatus and methods for reducing pain and/or retraining muscles |
US20040082847A1 (en) * | 2002-10-23 | 2004-04-29 | Mcdermott Kathleen B. | System and methods for identifying brain regions supporting language |
US6839594B2 (en) * | 2001-04-26 | 2005-01-04 | Biocontrol Medical Ltd | Actuation and control of limbs through motor nerve stimulation |
US20050004620A1 (en) * | 2002-12-09 | 2005-01-06 | Medtronic, Inc. | Implantable medical device with anti-infection agent |
US20050015129A1 (en) * | 1999-12-09 | 2005-01-20 | Mische Hans A. | Methods and devices for the treatment of neurological and physiological disorders |
US20050021107A1 (en) * | 2001-03-08 | 2005-01-27 | Firlik Andrew D. | Methods and apparatus for effectuating a lasting change in a neural-function of a patient |
US20050021105A1 (en) * | 2000-07-13 | 2005-01-27 | Firlik Andrew D. | Methods and apparatus for effectuating a change in a neural-function of a patient |
US20050021118A1 (en) * | 2000-07-13 | 2005-01-27 | Chris Genau | Apparatuses and systems for applying electrical stimulation to a patient |
US20050021104A1 (en) * | 1998-08-05 | 2005-01-27 | Dilorenzo Daniel John | Apparatus and method for closed-loop intracranial stimulation for optimal control of neurological disease |
US20050033378A1 (en) * | 2002-12-09 | 2005-02-10 | Sheffield Warren Douglas | Methods for treating and/or collecting information regarding neurological disorders, including language disorders |
US6873872B2 (en) * | 1999-12-07 | 2005-03-29 | George Mason University | Adaptive electric field modulation of neural systems |
US20050070971A1 (en) * | 2003-08-01 | 2005-03-31 | Brad Fowler | Apparatus and methods for applying neural stimulation to a patient |
US20050075679A1 (en) * | 2002-09-30 | 2005-04-07 | Gliner Bradford E. | Methods and apparatuses for treating neurological disorders by electrically stimulating cells implanted in the nervous system |
US20050075680A1 (en) * | 2003-04-18 | 2005-04-07 | Lowry David Warren | Methods and systems for intracranial neurostimulation and/or sensing |
US20060015153A1 (en) * | 2004-07-15 | 2006-01-19 | Gliner Bradford E | Systems and methods for enhancing or affecting neural stimulation efficiency and/or efficacy |
US6990377B2 (en) * | 2003-04-24 | 2006-01-24 | Northstar Neuroscience, Inc. | Systems and methods for facilitating and/or effectuating development, rehabilitation, restoration, and/or recovery of visual function through neural stimulation |
US6996261B2 (en) * | 2001-01-30 | 2006-02-07 | Decharms R Christopher | Methods for physiological monitoring, training, exercise and regulation |
US7006859B1 (en) * | 2002-07-20 | 2006-02-28 | Flint Hills Scientific, L.L.C. | Unitized electrode with three-dimensional multi-site, multi-modal capabilities for detection and control of brain state changes |
US7010351B2 (en) * | 2000-07-13 | 2006-03-07 | Northstar Neuroscience, Inc. | Methods and apparatus for effectuating a lasting change in a neural-function of a patient |
US7024247B2 (en) * | 2001-10-15 | 2006-04-04 | Northstar Neuroscience, Inc. | Systems and methods for reducing the likelihood of inducing collateral neural activity during neural stimulation threshold test procedures |
US20060241717A1 (en) * | 2001-08-30 | 2006-10-26 | Whitehurst Todd K | Treatment of movement disorders by extra dural motor cortex stimulation |
US7184840B2 (en) * | 2002-04-22 | 2007-02-27 | Medtronic, Inc. | Implantable lead with isolated contact coupling |
US20070088403A1 (en) * | 2005-10-19 | 2007-04-19 | Allen Wyler | Methods and systems for establishing parameters for neural stimulation |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2716226A (en) | 1951-06-22 | 1955-08-23 | Reiner Electronics Co Inc | Electrical solderless connector |
US2721316A (en) | 1953-06-09 | 1955-10-18 | Joseph D Shaw | Method and means for aiding the blind |
US3628193A (en) | 1969-02-19 | 1971-12-21 | Inst Of Medical Sciences The | Tactile image projection system |
US3850161A (en) | 1973-04-09 | 1974-11-26 | S Liss | Method and apparatus for monitoring and counteracting excess brain electrical energy to prevent epileptic seizures and the like |
US3918461A (en) | 1974-01-31 | 1975-11-11 | Irving S Cooper | Method for electrically stimulating the human brain |
US4030509A (en) | 1975-09-30 | 1977-06-21 | Mieczyslaw Mirowski | Implantable electrodes for accomplishing ventricular defibrillation and pacing and method of electrode implantation and utilization |
US4125116A (en) | 1977-02-14 | 1978-11-14 | The Johns Hopkins University | Human tissue stimulation electrode structure |
US4214804A (en) | 1978-09-25 | 1980-07-29 | Daig Corporation | Press fit electrical connection apparatus |
US4474186A (en) | 1979-07-17 | 1984-10-02 | Georgetown University | Computerized electro-oculographic (CEOG) system with feedback control of stimuli |
US4340038A (en) | 1980-12-15 | 1982-07-20 | Pacesetter Systems, Inc. | Magnetic field concentration means and method for an implanted device |
US4542752A (en) | 1983-04-22 | 1985-09-24 | Cordis Corporation | Implantable device having porous surface with carbon coating |
US4702254A (en) | 1983-09-14 | 1987-10-27 | Jacob Zabara | Neurocybernetic prosthesis |
US4844075A (en) | 1984-01-09 | 1989-07-04 | Pain Suppression Labs, Inc. | Transcranial stimulation for the treatment of cerebral palsy |
US4607639A (en) | 1984-05-18 | 1986-08-26 | Regents Of The University Of California | Method and system for controlling bladder evacuation |
US5054906A (en) | 1986-01-17 | 1991-10-08 | Brimfield Precision, Inc. | Indirectly illuminating ophthalmological speculum |
US4969468A (en) | 1986-06-17 | 1990-11-13 | Alfred E. Mann Foundation For Scientific Research | Electrode array for use in connection with a living body and method of manufacture |
US4869255A (en) | 1987-12-04 | 1989-09-26 | Ad-Tech Medical Instrument Corp. | Electrical connection device |
US4865048A (en) | 1987-12-31 | 1989-09-12 | Eckerson Harold D | Method and apparatus for drug free neurostimulation |
DE3914662A1 (en) | 1989-05-03 | 1990-11-08 | Alt Eckhard | DEVICE FOR TRANSMITTING ELECTRICAL SIGNALS BETWEEN AN IMPLANTABLE MEDICAL DEVICE AND ELECTRICALLY EXPENSIBLE HUMAN TISSUE |
US5024226A (en) | 1989-08-17 | 1991-06-18 | Critikon, Inc. | Epidural oxygen sensor |
US5063932A (en) | 1989-10-03 | 1991-11-12 | Mieczyslaw Mirowski | Controlled discharge defibrillation electrode |
US5215088A (en) | 1989-11-07 | 1993-06-01 | The University Of Utah | Three-dimensional electrode device |
US5271417A (en) | 1990-01-23 | 1993-12-21 | Cardiac Pacemakers, Inc. | Defibrillation electrode having smooth current distribution |
US5031618A (en) | 1990-03-07 | 1991-07-16 | Medtronic, Inc. | Position-responsive neuro stimulator |
US5044368A (en) | 1990-04-23 | 1991-09-03 | Ad-Tech Medical Instrument Corporation | Diagnostic electrode for use with magnetic resonance imaging |
US5121754A (en) | 1990-08-21 | 1992-06-16 | Medtronic, Inc. | Lateral displacement percutaneously inserted epidural lead |
US5224491A (en) | 1991-01-07 | 1993-07-06 | Medtronic, Inc. | Implantable electrode for location within a blood vessel |
US5269303A (en) | 1991-02-22 | 1993-12-14 | Cyberonics, Inc. | Treatment of dementia by nerve stimulation |
US5215086A (en) | 1991-05-03 | 1993-06-01 | Cyberonics, Inc. | Therapeutic treatment of migraine symptoms by stimulation |
US5255678A (en) | 1991-06-21 | 1993-10-26 | Ecole Polytechnique | Mapping electrode balloon |
US5750376A (en) | 1991-07-08 | 1998-05-12 | Neurospheres Holdings Ltd. | In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny |
US5169384A (en) | 1991-08-16 | 1992-12-08 | Bosniak Stephen L | Apparatus for facilitating post-traumatic, post-surgical, and/or post-inflammatory healing of tissue |
US5263967B1 (en) | 1992-05-15 | 2000-12-19 | Brimfield Prec Inc | Medical instrument with dual action drive |
US5476494A (en) | 1992-09-11 | 1995-12-19 | Massachusetts Institute Of Technology | Low pressure neural contact structure |
US5441528A (en) | 1992-09-25 | 1995-08-15 | Symtonic, S.A. | Method and system for applying low energy emission therapy |
US5370672A (en) | 1992-10-30 | 1994-12-06 | The Johns Hopkins University | Computer-controlled neurological stimulation system |
US5358513A (en) | 1992-12-09 | 1994-10-25 | Medtronic, Inc. | Parameter selection and electrode placement of neuromuscular electrical stimulation apparatus |
SE9203734D0 (en) | 1992-12-11 | 1992-12-11 | Siemens Elema Ab | defibrillation |
US5537512A (en) | 1993-05-26 | 1996-07-16 | Northrop Grumman Corporation | Neural network elements |
US5540736A (en) | 1993-08-02 | 1996-07-30 | Haimovich; Yechiel | Transcranial electrostimulation apparatus having two electrode pairs and independent current generators |
US5464446A (en) | 1993-10-12 | 1995-11-07 | Medtronic, Inc. | Brain lead anchoring system |
US5697975A (en) | 1994-02-09 | 1997-12-16 | The University Of Iowa Research Foundation | Human cerebral cortex neural prosthetic for tinnitus |
US5562708A (en) | 1994-04-21 | 1996-10-08 | Medtronic, Inc. | Method and apparatus for treatment of atrial fibrillation |
US5769778A (en) | 1994-04-22 | 1998-06-23 | Somatics, Inc. | Medical magnetic non-convulsive stimulation therapy |
US5549655A (en) | 1994-09-21 | 1996-08-27 | Medtronic, Inc. | Method and apparatus for synchronized treatment of obstructive sleep apnea |
US5540734A (en) | 1994-09-28 | 1996-07-30 | Zabara; Jacob | Cranial nerve stimulation treatments using neurocybernetic prosthesis |
US5522864A (en) | 1994-10-25 | 1996-06-04 | Wallace; Larry B. | Apparatus and method for ocular treatment |
US5520190A (en) | 1994-10-31 | 1996-05-28 | Ventritex, Inc. | Cardiac blood flow sensor and method |
US5772591A (en) | 1995-06-06 | 1998-06-30 | Patient Comfort, Inc. | Electrode assembly for signaling a monitor |
US5769861A (en) * | 1995-09-28 | 1998-06-23 | Brainlab Med. Computersysteme Gmbh | Method and devices for localizing an instrument |
US5782873A (en) | 1995-10-11 | 1998-07-21 | Trustees Of Boston University | Method and apparatus for improving the function of sensory cells |
US5824030A (en) | 1995-12-21 | 1998-10-20 | Pacesetter, Inc. | Lead with inter-electrode spacing adjustment |
US5628317A (en) | 1996-04-04 | 1997-05-13 | Medtronic, Inc. | Ultrasonic techniques for neurostimulator control |
US5702429A (en) | 1996-04-04 | 1997-12-30 | Medtronic, Inc. | Neural stimulation techniques with feedback |
US5824021A (en) | 1996-04-25 | 1998-10-20 | Medtronic Inc. | Method and apparatus for providing feedback to spinal cord stimulation for angina |
US5683422A (en) | 1996-04-25 | 1997-11-04 | Medtronic, Inc. | Method and apparatus for treating neurodegenerative disorders by electrical brain stimulation |
US5782798A (en) | 1996-06-26 | 1998-07-21 | Medtronic, Inc. | Techniques for treating eating disorders by brain stimulation and drug infusion |
US5797970A (en) | 1996-09-04 | 1998-08-25 | Medtronic, Inc. | System, adaptor and method to provide medical electrical stimulation |
US5843148A (en) | 1996-09-27 | 1998-12-01 | Medtronic, Inc. | High resolution brain stimulation lead and method of use |
US5752979A (en) | 1996-11-01 | 1998-05-19 | Medtronic, Inc. | Method of controlling epilepsy by brain stimulation |
WO1999040841A1 (en) * | 1998-02-11 | 1999-08-19 | Non-Invasive Technology, Inc. | Imaging and characterization of brain tissue |
US6144875A (en) * | 1999-03-16 | 2000-11-07 | Accuray Incorporated | Apparatus and method for compensating for respiratory and patient motion during treatment |
-
2003
- 2003-12-09 US US10/731,731 patent/US7299096B2/en not_active Expired - Lifetime
-
2007
- 2007-10-04 US US11/867,654 patent/US7962218B2/en not_active Expired - Fee Related
-
2011
- 2011-05-04 US US13/100,646 patent/US20110208263A1/en not_active Abandoned
Patent Citations (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3650276A (en) * | 1969-03-26 | 1972-03-21 | Inst Demedicina Si Farmacie | Method and apparatus, including a flexible electrode, for the electric neurostimulation of the neurogenic bladder |
US4140133A (en) * | 1977-04-26 | 1979-02-20 | Moskovsky Oblastnoi Nauchno-Issledovatelsky Institut Akusherstva I Ginekolog Ii | Device for pulse current action on central nervous system |
US4245645A (en) * | 1977-09-28 | 1981-01-20 | Arseneault Pierre Michel | Self-locking cerebral electrical probe |
US4431000A (en) * | 1978-11-29 | 1984-02-14 | Gatron Corporation | Transcutaneous nerve stimulator with pseusorandom pulse generator |
US4308868A (en) * | 1980-05-27 | 1982-01-05 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Implantable electrical device |
US4328813A (en) * | 1980-10-20 | 1982-05-11 | Medtronic, Inc. | Brain lead anchoring system |
US4590946A (en) * | 1984-06-14 | 1986-05-27 | Biomed Concepts, Inc. | Surgically implantable electrode for nerve bundles |
US4646744A (en) * | 1984-06-29 | 1987-03-03 | Zion Foundation | Method and treatment with transcranially applied electrical signals |
US4903702A (en) * | 1988-10-17 | 1990-02-27 | Ad-Tech Medical Instrument Corporation | Brain-contact for sensing epileptogenic foci with improved accuracy |
US5002053A (en) * | 1989-04-21 | 1991-03-26 | University Of Arkansas | Method of and device for inducing locomotion by electrical stimulation of the spinal cord |
US5314458A (en) * | 1990-06-01 | 1994-05-24 | University Of Michigan | Single channel microstimulator |
US5282468A (en) * | 1990-06-07 | 1994-02-01 | Medtronic, Inc. | Implantable neural electrode |
US5092835A (en) * | 1990-07-06 | 1992-03-03 | Schurig Janet L S | Brain and nerve healing power apparatus and method |
US5618531A (en) * | 1990-10-19 | 1997-04-08 | New York University | Method for increasing the viability of cells which are administered to the brain or spinal cord |
US5299569A (en) * | 1991-05-03 | 1994-04-05 | Cyberonics, Inc. | Treatment of neuropsychiatric disorders by nerve stimulation |
US5304206A (en) * | 1991-11-18 | 1994-04-19 | Cyberonics, Inc. | Activation techniques for implantable medical device |
US5193540A (en) * | 1991-12-18 | 1993-03-16 | Alfred E. Mann Foundation For Scientific Research | Structure and method of manufacture of an implantable microstimulator |
US5184620A (en) * | 1991-12-26 | 1993-02-09 | Marquette Electronics, Inc. | Method of using a multiple electrode pad assembly |
US5406957A (en) * | 1992-02-05 | 1995-04-18 | Tansey; Michael A. | Electroencephalic neurofeedback apparatus for training and tracking of cognitive states |
US5303705A (en) * | 1992-05-01 | 1994-04-19 | Nenov Valeriy I | Evoked 23NA MR imaging of sodium currents in the brain |
US5411540A (en) * | 1993-06-03 | 1995-05-02 | Massachusetts Institute Of Technology | Method and apparatus for preferential neuron stimulation |
US5593432A (en) * | 1993-06-23 | 1997-01-14 | Neuroware Therapy International, Inc. | Method for neurostimulation for pain alleviation |
US5417719A (en) * | 1993-08-25 | 1995-05-23 | Medtronic, Inc. | Method of using a spinal cord stimulation lead |
US5405375A (en) * | 1994-01-21 | 1995-04-11 | Incontrol, Inc. | Combined mapping, pacing, and defibrillating catheter |
US5601611A (en) * | 1994-08-05 | 1997-02-11 | Ventritex, Inc. | Optical blood flow measurement apparatus and method and implantable defibrillator incorporating same |
US5722401A (en) * | 1994-10-19 | 1998-03-03 | Cardiac Pathways Corporation | Endocardial mapping and/or ablation catheter probe |
US5885976A (en) * | 1995-05-08 | 1999-03-23 | Sandyk; Reuven | Methods useful for the treatment of neurological and mental disorders related to deficient serotonin neurotransmission and impaired pineal melatonin functions |
US5591216A (en) * | 1995-05-19 | 1997-01-07 | Medtronic, Inc. | Method for treatment of sleep apnea by electrical stimulation |
US5707334A (en) * | 1995-08-21 | 1998-01-13 | Young; Robert B. | Method of treating amygdala related transitory disorders |
US6205360B1 (en) * | 1995-09-07 | 2001-03-20 | Cochlear Limited | Apparatus and method for automatically determining stimulation parameters |
US5611350A (en) * | 1996-02-08 | 1997-03-18 | John; Michael S. | Method and apparatus for facilitating recovery of patients in deep coma |
US5713922A (en) * | 1996-04-25 | 1998-02-03 | Medtronic, Inc. | Techniques for adjusting the locus of excitation of neural tissue in the spinal cord or brain |
US5716377A (en) * | 1996-04-25 | 1998-02-10 | Medtronic, Inc. | Method of treating movement disorders by brain stimulation |
US5711316A (en) * | 1996-04-30 | 1998-01-27 | Medtronic, Inc. | Method of treating movement disorders by brain infusion |
US5735814A (en) * | 1996-04-30 | 1998-04-07 | Medtronic, Inc. | Techniques of treating neurodegenerative disorders by brain infusion |
US5713923A (en) * | 1996-05-13 | 1998-02-03 | Medtronic, Inc. | Techniques for treating epilepsy by brain stimulation and drug infusion |
US6040180A (en) * | 1996-05-23 | 2000-03-21 | Neuralstem Biopharmaceuticals, Ltd. | In vitro generation of differentiated neurons from cultures of mammalian multipotential CNS stem cells |
US6556868B2 (en) * | 1996-05-31 | 2003-04-29 | The Board Of Trustees Of Southern Illinois University | Methods for improving learning or memory by vagus nerve stimulation |
US6339725B1 (en) * | 1996-05-31 | 2002-01-15 | The Board Of Trustees Of Southern Illinois University | Methods of modulating aspects of brain neural plasticity by vagus nerve stimulation |
US6021352A (en) * | 1996-06-26 | 2000-02-01 | Medtronic, Inc, | Diagnostic testing methods and apparatus for implantable therapy devices |
US5865842A (en) * | 1996-08-29 | 1999-02-02 | Medtronic, Inc. | System and method for anchoring brain stimulation lead or catheter |
US6026326A (en) * | 1997-01-13 | 2000-02-15 | Medtronic, Inc. | Apparatus and method for treating chronic constipation |
US5871517A (en) * | 1997-01-15 | 1999-02-16 | Somatics, Inc. | Convulsive therapy apparatus to stimulate and monitor the extent of therapeutic value of the treatment |
US5893883A (en) * | 1997-04-30 | 1999-04-13 | Medtronic, Inc. | Portable stimulation screening device for screening therapeutic effect of electrical stimulation on a patient user during normal activities of the patient user |
US6042579A (en) * | 1997-04-30 | 2000-03-28 | Medtronic, Inc. | Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain |
US6016449A (en) * | 1997-10-27 | 2000-01-18 | Neuropace, Inc. | System for treatment of neurological disorders |
US6360122B1 (en) * | 1997-10-27 | 2002-03-19 | Neuropace, Inc. | Data recording methods for an implantable device |
US6354299B1 (en) * | 1997-10-27 | 2002-03-12 | Neuropace, Inc. | Implantable device for patient communication |
US6011996A (en) * | 1998-01-20 | 2000-01-04 | Medtronic, Inc | Dual electrode lead and method for brain target localization in functional stereotactic brain surgery |
US6221908B1 (en) * | 1998-03-12 | 2001-04-24 | Scientific Learning Corporation | System for stimulating brain plasticity |
US6018682A (en) * | 1998-04-30 | 2000-01-25 | Medtronic, Inc. | Implantable seizure warning system |
US5886769A (en) * | 1998-05-18 | 1999-03-23 | Zolten; A. J. | Method of training and rehabilitating brain function using hemi-lenses |
US6198958B1 (en) * | 1998-06-11 | 2001-03-06 | Beth Israel Deaconess Medical Center, Inc. | Method and apparatus for monitoring a magnetic resonance image during transcranial magnetic stimulation |
US6035236A (en) * | 1998-07-13 | 2000-03-07 | Bionergy Therapeutics, Inc. | Methods and apparatus for electrical microcurrent stimulation therapy |
US6366813B1 (en) * | 1998-08-05 | 2002-04-02 | Dilorenzo Daniel J. | Apparatus and method for closed-loop intracranical stimulation for optimal control of neurological disease |
US20050021104A1 (en) * | 1998-08-05 | 2005-01-27 | Dilorenzo Daniel John | Apparatus and method for closed-loop intracranial stimulation for optimal control of neurological disease |
US6190893B1 (en) * | 1998-09-18 | 2001-02-20 | Massachusetts Institute Of Technology | Electroactive materials for stimulation of biological activity of bone marrow stromal cells |
US6507755B1 (en) * | 1998-12-01 | 2003-01-14 | Neurometrix, Inc. | Apparatus and method for stimulating human tissue |
US6052624A (en) * | 1999-01-07 | 2000-04-18 | Advanced Bionics Corporation | Directional programming for implantable electrode arrays |
US6725094B2 (en) * | 1999-03-24 | 2004-04-20 | Lloyd R. Saberski | Apparatus and methods for reducing pain and/or retraining muscles |
US6055456A (en) * | 1999-04-29 | 2000-04-25 | Medtronic, Inc. | Single and multi-polar implantable lead for sacral nerve electrical stimulation |
US6210417B1 (en) * | 1999-04-29 | 2001-04-03 | Medtronic, Inc. | Medical lead positioning and anchoring system |
US6176242B1 (en) * | 1999-04-30 | 2001-01-23 | Medtronic Inc | Method of treating manic depression by brain infusion |
US6505075B1 (en) * | 1999-05-29 | 2003-01-07 | Richard L. Weiner | Peripheral nerve stimulation method |
US6539263B1 (en) * | 1999-06-11 | 2003-03-25 | Cornell Research Foundation, Inc. | Feedback mechanism for deep brain stimulation |
US6873872B2 (en) * | 1999-12-07 | 2005-03-29 | George Mason University | Adaptive electric field modulation of neural systems |
US6375666B1 (en) * | 1999-12-09 | 2002-04-23 | Hans Alois Mische | Methods and devices for treatment of neurological disorders |
US20050015129A1 (en) * | 1999-12-09 | 2005-01-20 | Mische Hans A. | Methods and devices for the treatment of neurological and physiological disorders |
US6356792B1 (en) * | 2000-01-20 | 2002-03-12 | Electro Core Technologies, Llc | Skull mounted electrode lead securing assembly |
US6708064B2 (en) * | 2000-02-24 | 2004-03-16 | Ali R. Rezai | Modulation of the brain to affect psychiatric disorders |
US6690974B2 (en) * | 2000-04-05 | 2004-02-10 | Neuropace, Inc. | Stimulation signal generator for an implantable device |
US6353754B1 (en) * | 2000-04-24 | 2002-03-05 | Neuropace, Inc. | System for the creation of patient specific templates for epileptiform activity detection |
US6687525B2 (en) * | 2000-06-07 | 2004-02-03 | New York University | Method and system for diagnosing and treating thalamocortical dysrhythmia |
US6549814B1 (en) * | 2000-06-09 | 2003-04-15 | Juergen Strutz | Blade electrode array for insertion under soft tissue of lateral wall of cochlea |
US20050021118A1 (en) * | 2000-07-13 | 2005-01-27 | Chris Genau | Apparatuses and systems for applying electrical stimulation to a patient |
US20040073270A1 (en) * | 2000-07-13 | 2004-04-15 | Firlik Andrew D. | Methods and apparatus for effectuating a lasting change in a neural-function of a patient |
US7010351B2 (en) * | 2000-07-13 | 2006-03-07 | Northstar Neuroscience, Inc. | Methods and apparatus for effectuating a lasting change in a neural-function of a patient |
US20050021106A1 (en) * | 2000-07-13 | 2005-01-27 | Firlik Andrew D. | Methods and apparatus for effectuating a lasting change in a neural-function of a patient |
US20050021105A1 (en) * | 2000-07-13 | 2005-01-27 | Firlik Andrew D. | Methods and apparatus for effectuating a change in a neural-function of a patient |
US20020028072A1 (en) * | 2000-09-01 | 2002-03-07 | Ritsuo Kashiyama | Camera having illumination device and control function for same |
US6529774B1 (en) * | 2000-11-09 | 2003-03-04 | Neuropace, Inc. | Extradural leads, neurostimulator assemblies, and processes of using them for somatosensory and brain stimulation |
US6996261B2 (en) * | 2001-01-30 | 2006-02-07 | Decharms R Christopher | Methods for physiological monitoring, training, exercise and regulation |
US20050021107A1 (en) * | 2001-03-08 | 2005-01-27 | Firlik Andrew D. | Methods and apparatus for effectuating a lasting change in a neural-function of a patient |
US6839594B2 (en) * | 2001-04-26 | 2005-01-04 | Biocontrol Medical Ltd | Actuation and control of limbs through motor nerve stimulation |
US20060241717A1 (en) * | 2001-08-30 | 2006-10-26 | Whitehurst Todd K | Treatment of movement disorders by extra dural motor cortex stimulation |
US6684105B2 (en) * | 2001-08-31 | 2004-01-27 | Biocontrol Medical, Ltd. | Treatment of disorders by unidirectional nerve stimulation |
US20030078633A1 (en) * | 2001-09-28 | 2003-04-24 | Firlik Andrew D. | Methods and implantable apparatus for electrical therapy |
US20030074032A1 (en) * | 2001-10-15 | 2003-04-17 | Gliner Bradford Evan | Neural stimulation system and method responsive to collateral neural activity |
US7024247B2 (en) * | 2001-10-15 | 2006-04-04 | Northstar Neuroscience, Inc. | Systems and methods for reducing the likelihood of inducing collateral neural activity during neural stimulation threshold test procedures |
US7184840B2 (en) * | 2002-04-22 | 2007-02-27 | Medtronic, Inc. | Implantable lead with isolated contact coupling |
US7006859B1 (en) * | 2002-07-20 | 2006-02-28 | Flint Hills Scientific, L.L.C. | Unitized electrode with three-dimensional multi-site, multi-modal capabilities for detection and control of brain state changes |
US20050075679A1 (en) * | 2002-09-30 | 2005-04-07 | Gliner Bradford E. | Methods and apparatuses for treating neurological disorders by electrically stimulating cells implanted in the nervous system |
US20040082847A1 (en) * | 2002-10-23 | 2004-04-29 | Mcdermott Kathleen B. | System and methods for identifying brain regions supporting language |
US20050033378A1 (en) * | 2002-12-09 | 2005-02-10 | Sheffield Warren Douglas | Methods for treating and/or collecting information regarding neurological disorders, including language disorders |
US20050004620A1 (en) * | 2002-12-09 | 2005-01-06 | Medtronic, Inc. | Implantable medical device with anti-infection agent |
US20050075680A1 (en) * | 2003-04-18 | 2005-04-07 | Lowry David Warren | Methods and systems for intracranial neurostimulation and/or sensing |
US6990377B2 (en) * | 2003-04-24 | 2006-01-24 | Northstar Neuroscience, Inc. | Systems and methods for facilitating and/or effectuating development, rehabilitation, restoration, and/or recovery of visual function through neural stimulation |
US20050070971A1 (en) * | 2003-08-01 | 2005-03-31 | Brad Fowler | Apparatus and methods for applying neural stimulation to a patient |
US20060015153A1 (en) * | 2004-07-15 | 2006-01-19 | Gliner Bradford E | Systems and methods for enhancing or affecting neural stimulation efficiency and/or efficacy |
US20070088403A1 (en) * | 2005-10-19 | 2007-04-19 | Allen Wyler | Methods and systems for establishing parameters for neural stimulation |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10729903B2 (en) | 2014-08-15 | 2020-08-04 | Axonics Modulation Technologies, Inc. | Methods for determining neurostimulation electrode configurations based on neural localization |
US9555246B2 (en) | 2014-08-15 | 2017-01-31 | Axonics Modulation Technologies, Inc. | Electromyographic lead positioning and stimulation titration in a nerve stimulation system for treatment of overactive bladder |
US9561372B2 (en) | 2014-08-15 | 2017-02-07 | Axonics Modulation Technologies, Inc. | Electromyographic lead positioning and stimulation titration in a nerve stimulation system for treatment of overactive bladder |
US9855423B2 (en) | 2014-08-15 | 2018-01-02 | Axonics Modulation Technologies, Inc. | Systems and methods for neurostimulation electrode configurations based on neural localization |
US10092762B2 (en) | 2014-08-15 | 2018-10-09 | Axonics Modulation Technologies, Inc. | Integrated electromyographic clinician programmer for use with an implantable neurostimulator |
US10406369B2 (en) | 2014-08-15 | 2019-09-10 | Axonics Modulation Technologies, Inc. | Electromyographic lead positioning and stimulation titration in a nerve stimulation system for treatment of overactive bladder |
US9533155B2 (en) | 2014-08-15 | 2017-01-03 | Axonics Modulation Technologies, Inc. | Methods for determining neurostimulation electrode configurations based on neural localization |
US11116985B2 (en) | 2014-08-15 | 2021-09-14 | Axonics, Inc. | Clinician programmer for use with an implantable neurostimulation lead |
US11497916B2 (en) | 2014-08-15 | 2022-11-15 | Axonics, Inc. | Electromyographic lead positioning and stimulation titration in a nerve stimulation system for treatment of overactive bladder |
US11730411B2 (en) | 2014-08-15 | 2023-08-22 | Axonics, Inc. | Methods for determining neurostimulation electrode configurations based on neural localization |
US11439829B2 (en) | 2019-05-24 | 2022-09-13 | Axonics, Inc. | Clinician programmer methods and systems for maintaining target operating temperatures |
US11848090B2 (en) | 2019-05-24 | 2023-12-19 | Axonics, Inc. | Trainer for a neurostimulator programmer and associated methods of use with a neurostimulation system |
WO2020255142A3 (en) * | 2019-06-18 | 2021-03-04 | Eeg-Sense Ltd. | Method and system for measuring eeg signals |
Also Published As
Publication number | Publication date |
---|---|
US7962218B2 (en) | 2011-06-14 |
US20080195175A1 (en) | 2008-08-14 |
US7299096B2 (en) | 2007-11-20 |
US20040181263A1 (en) | 2004-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7962218B2 (en) | System and method for treating Parkinson's Disease and other movement disorders | |
US6959215B2 (en) | Methods for treating essential tremor | |
US7565200B2 (en) | Systems and methods for selecting stimulation sites and applying treatment, including treatment of symptoms of Parkinson's disease, other movement disorders, and/or drug side effects | |
US10004901B2 (en) | Systems and methods for enhancing or optimizing neural stimulation therapy for treating symptoms of parkinson's disease and/or other movement disorders | |
US8126562B2 (en) | Apparatus and methods for applying neural stimulation to a patient | |
US7107097B2 (en) | Articulated neural electrode assembly | |
WO2004052448A1 (en) | System and method for treating parkinson's disease and other movement disorders | |
US7623927B2 (en) | Modulation of the brain to affect psychiatric disorders | |
US20080033503A1 (en) | Electrode configurations for reducing invasiveness and/or enhancing neural stimulation efficacy, and associated methods | |
WO2004052449A1 (en) | Methods for treating neurological language disorders | |
US7774068B1 (en) | System and method for treating movement disorders, including restless leg syndrome |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |